<SEC-DOCUMENT>0001213900-25-039303.txt : 20250502
<SEC-HEADER>0001213900-25-039303.hdr.sgml : 20250502
<ACCEPTANCE-DATETIME>20250502171147
ACCESSION NUMBER:		0001213900-25-039303
CONFORMED SUBMISSION TYPE:	F-3
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20250502
DATE AS OF CHANGE:		20250502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286956
		FILM NUMBER:		25909886

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-3
<SEQUENCE>1
<FILENAME>ea0240501-f3_enlivex.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<B>As filed with the Securities and Exchange Commission on May 2, 2025</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM F-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>ENLIVEX
THERAPEUTICS LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact Name of Registrant as Specified in Its
Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of Registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State of Israel</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<BR>
Incorporation or Organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification Number)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>14 Einstein Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ness Ziona</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Israel 7403618</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: +972.2.6708072</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address and telephone number of Registrant&rsquo;s
principal executive offices)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cogency Global Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>122 East 42nd Street, 18th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10168</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (212) 947-7200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, and telephone number of agent for
service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>Copies of communications
to:</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Drew M. Altman, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Win Rutherfurd, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Greenberg Traurig, P.A.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>333 S.E. 2<SUP>nd</SUP> Avenue</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 4400</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Miami, Florida 33131</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(305) 579-0500</B></P></TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sharon Rosen, Adv. </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FISCHER (FBC &amp; Co.)</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>146 Menachem Begin Street Tel&nbsp;Aviv</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>6492103,&nbsp;Israel
    </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+972 -3-6944111 </B></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Approximate Date of Commencement
of Proposed Sale to the Public</B>: From time to time after this Registration Statement is declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">If
only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. </FONT>&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
</FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">If
this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-size: 10pt">Emerging
growth company </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">If an emerging
growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards&dagger; provided pursuant
to Section 7(a)(2)(B) of the Securities Act. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&dagger; The term &ldquo;new or revised financial
accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The Registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further
amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a)
of the Securities Act or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This registration statement
on Form F-3 is being filed in accordance with Rule 415(a)(6) under the Securities Act of 1933, as amended, to replace the Company&rsquo;s
currently effective Registration Statement on Form F-3 (File No. 333-264561), which expires on May 5, 2025 pursuant to Rule 415(a)(5)
promulgated under such Act. This filing contains two prospectuses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a base prospectus which covers
the offering and potential sale, subject to one or more future issuances of up to, in the aggregate, $300,000,000 of the registrant&rsquo;s
ordinary shares, warrants and units comprising any combination of these securities, including the issuance of our ordinary shares under
our Outstanding Registered Warrants (as defined in such base prospectus); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a sales agreement prospectus covering the offering and potential future issuance and sale of up to 8,800,000 ordinary shares that may be issued and sold under the registrant&rsquo;s existing Sales Agreement, dated December 30, 2022, by and among the registrant, Cantor Fitzgerald &amp; Co. and Citizens JMP Securities, LLC (the &ldquo;Sales Agreement&rdquo;);</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The base prospectus immediately
follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in
a prospectus supplement to the base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sales agreement prospectus
immediately follows the base prospectus. The ordinary shares that may be offered and potentially issued and sold under the sales agreement
prospectus is included in the $300,000,000 of securities that may be offered, issued and sold by the registrant under the base
prospectus. Upon termination of the Sales Agreement, any portion of the capacity included in the sales agreement prospectus that is not
sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy
these securities in any state where the offer or sale is not permitted</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="color: Red"><B>SUBJECT TO COMPLETION,
DATED MAY 2, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$300,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ENLIVEX THERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to time offer
to sell our ordinary shares, warrants and units described in this prospectus in one or more offerings. The aggregate initial offering
price of the securities that we may offer and sell under this prospectus will not exceed $300,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We refer to the ordinary shares,
warrants and units collectively as &ldquo;securities&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus provides a
general description of these securities, which we may offer and sell in amounts, at prices and on terms to be determined at the time of
sale and set forth in a supplement to this prospectus. Each time we sell the securities described in this prospectus, we will provide
specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change
information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you
invest in any of our securities. This prospectus may not be used to consummate a sale of our securities unless accompanied by an applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may offer the securities
from time through public or private transactions, and in the case of our ordinary shares, on or off the Nasdaq Capital Market, at prevailing
market prices or at privately negotiate prices. These securities may be offered and sold in the same offering or in separate offerings,
to or through underwriters, dealers and agents, or directly to purchasers. The names of any underwriters, dealers, or agents involved
in the sale of our securities registered hereunder and any applicable fees, commissions or discounts will be described in the applicable
prospectus supplement. Our net proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. For
general information about the distribution of securities offered, please see &ldquo;Plan of Distribution&rdquo; beginning on page 18.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are traded on the Nasdaq Capital Market and the
Tel Aviv Stock Exchange under the symbol &ldquo;ENLV.&rdquo; The last reported sale price of our ordinary shares on the Nasdaq Capital
Market on May 1, 2025 was $1.05 per share. The last reported sale price of our ordinary shares on the Tel Aviv Stock Exchange on April
30, 2025 was NIS 3.693 or $1.02 per share (based on the exchange rate reported by the Bank of Israel on the same day). As of May 1, 2025,
the aggregate market value of our outstanding ordinary shares held by non-affiliates was approximately $27,756,152.00 based on 23,849,935
outstanding ordinary shares as of March 31, 2025, of which approximately 22,750,944 ordinary shares were held by non-affiliates. We have
not offered any of our ordinary shares pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that
ends on, and includes, the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves risks. See &ldquo;RISK FACTORS&rdquo; beginning on page <FONT>2</FONT> for information
you should consider before investing in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 90%; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Company</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Ordinary Shares</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Warrants</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Units</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforceability of Civil Liabilities</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Documents by Reference</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_001"></A>About This Prospectus</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus is part of a &ldquo;shelf&rdquo; registration statement on Form F-3 that we filed with the United States Securities and Exchange
Commission, or the SEC. Under this shelf registration statement, we may sell any one or more or a combination of the securities described
in this prospectus in one or more offerings, up to a total dollar amount of $300,000,000. This prospectus provides you with only a general
description of the securities we may offer. Each time we use this prospectus to offer securities, we will provide a prospectus supplement
that contains specific information about any offering by us with respect to the securities registered hereunder. The prospectus supplement
may also add, update or change the information contained in this prospectus. Any statement that we make in this prospectus will be modified
or superseded by any inconsistent statement made by us in a prospectus supplement. You should read carefully both this prospectus, any
prospectus supplement and any free writing prospectus related to the applicable offering that is prepared by us or on our behalf or that
is otherwise authorized by us, together with additional information described under the heading &ldquo;Where You Can Find More Information&rdquo;
located on page 21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">You
should rely only on the information contained or incorporated by reference in this prospectus, any prospectus supplement and any free
writing prospectus related to the applicable offering of securities that is prepared by us or on our behalf or that is otherwise authorized
by us. We have not authorized any other person to provide you with different information. You must not rely upon any information or representation
not contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any free writing prospectus that
is prepared by us or on our behalf or that is otherwise authorized by us. This prospectus and any accompanying supplement to this prospectus
do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which
they relate, nor do this prospectus and any accompanying supplement constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should
not assume that the information contained in this prospectus and any accompanying prospectus supplement is accurate on any date subsequent
to the date set forth on the front of this prospectus and such accompanying prospectus supplement or that any information we have incorporated
by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and
any accompanying prospectus supplement are delivered, or securities sold, on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References in this prospectus
to the &ldquo;Registrant,&rdquo; the &ldquo;Company,&rdquo; &ldquo;Enlivex,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo;
refer to Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, and its consolidated subsidiaries, unless
the context requires otherwise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_002"></A>Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our securities
involves risks. Before deciding to purchase any of our securities, you should carefully consider the discussion of risks and uncertainties
under the heading &ldquo;Risk Factors&rdquo; contained in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024,
which is incorporated by reference in this prospectus, and under similar headings in our subsequently filed reports on Form 6-K and annual
reports on Form 20-F, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus
and in the other documents incorporated by reference in this prospectus. See the section entitled &ldquo;Where You Can Find More Information&rdquo;
in this prospectus. The risks and uncertainties we discuss in the documents incorporated by reference in this prospectus are those we
currently believe may materially affect our business, prospects, financial condition and results of operation. Additional risks and uncertainties
not presently known to us or that we currently believe are immaterial also may materially and adversely affect our business, prospects,
financial condition and results of operations.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_003"></A>Cautionary Statement
Regarding Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. These
forward-looking statements include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding the timing of clinical trials with respect to Allocetra&trade;;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding the progress of our clinical trials, including the duration, cost and whether such trials will be conducted at all;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our intention to successfully complete clinical trials in order to be in a position to submit applications for accelerated regulatory paths in the EU and the United States;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the possibility that we will apply in the future for regulatory approval for our current and any future product candidates we may develop, and the costs and timing of such regulatory approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the likelihood of regulatory approvals for any product candidate we may develop;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the timing, cost or other aspects of the commercial launch of any product candidate we may develop, including the possibility that we will build a commercial infrastructure to support commercialization of our current and any future product candidates we may develop;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">future sales of our product candidates or any other future products or product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to achieve favorable pricing for our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the potential for our product candidates to receive orphan drug designations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">that any product candidate we develop potentially offers effective solutions for various diseases;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether we will develop any future product candidates internally or through strategic partnerships;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding the manufacturing and supply of any product candidate for use in our clinical trials, and the commercial supply of those product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third-party payer reimbursement for our current or any future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our estimates regarding anticipated expenses, capital requirements and our needs for substantial additional financing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">patient market sizes and market adoption of our current or any future product candidates by physicians and patients;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">completion and receiving favorable results of clinical trials for our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">protection of our intellectual property, including issuance of patents to us by the United States Patent and Trademark Office, and other governmental patent agencies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our intention to pursue marketing and orphan drug exclusivity periods that are available to us under regulatory provisions in certain countries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the development and approval of the use of our current or any future product candidates for any indication;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding commercial and pre-commercial activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding collaborations, licensing, acquisitions, and strategic operations; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our liquidity; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the impact of the economic, public health, political and security situation in Israel, the U.S. and other countries in which we may operate or obtain approvals for Allocetra<SUP>TM</SUP>&nbsp;and any future product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, forward-looking
statements are identified by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;hope,&rdquo; &ldquo;targets,&rdquo; &ldquo;potential,&rdquo; &ldquo;goal&rdquo; or &ldquo;continue&rdquo; or the negative of these
terms or other comparable terminology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors
that may cause actual results or performance to differ materially from those suggested in such forward-looking statements. These statements
are current only as of the date of this prospectus and are subject to known and unknown risks, uncertainties, and other factors that may
cause our actual results, levels of activity, performance or achievements to be materially different from those suggested in the forward-looking
statements. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions
of future research or trials would not suggest different conclusions or that historic results referred to in this prospectus or in our
Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which is incorporated by reference in this prospectus, would not
be interpreted differently in light of additional research, clinical and preclinical trials results. Factors which could cause actual
results to differ materially from those indicated by the forward-looking statements include those factors described under the caption
&ldquo;Risk Factors&rdquo; in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which is incorporated by reference
in this prospectus, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus
and in the other documents incorporated by reference in this prospectus. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this prospectus. &nbsp;Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by
law, we do not intend to (and expressly disclaim any such obligation to) update or revise any of the forward-looking statements, whether
as a result of new information, future events or otherwise, after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_004"></A>Our Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a clinical-stage
macrophage reprogramming immunotherapy company, developing Allocetra<SUP>TM</SUP>, a universal, off-the-shelf cell therapy designed to
reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for
immune system rebalancing and resolution of debilitating and life-threatening conditions. Non-homeostatic macrophages contribute significantly
to the severity of a given disease. By restoring macrophage homeostasis, Allocetra&trade; has the potential to provide a novel immunotherapeutic
mechanism of action for debilitating and life-threatening clinical indications that are defined as &ldquo;unmet medical needs,&rdquo;
as a stand-alone therapy or in combination with leading therapeutic agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Macrophages are tissue-resident
or infiltrating immune cells critical for innate immunity, normal tissue development, and repair of damaged tissue. Macrophages&rsquo;
function is a result of their original designation, their local micro-environment, and the type of metabolites, substances or pathogens
to which they are exposed. When reprogrammed out of their homeostatic state, macrophages contribute to the pathophysiology of multiple
inflammatory diseases, including osteoarthritis, sepsis and various inflammatory disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the Company&rsquo;s
primary innovative immunotherapy, Allocetra<SUP>TM</SUP>, represents a paradigm shift in macrophage reprogramming, moving from targeting
a specific subset of macrophages or a specific pathway affecting macrophage activity, to a fundamental view of macrophage homeostasis.
Restoring macrophage homeostasis may induce the immune system to rebalance itself to normal levels of operation, thereby promoting disease
resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is focused on
osteoarthritis as its main chronic inflammatory indication. Osteoarthritis is a degenerative disease, characterized by low-grade inflammation,
that affects more than 32.5 million people in the United States. Treatment of osteoarthritis represents a substantial unmet medical need,
particularly non-invasive treatments, as current therapeutic options are largely limited to pain management, lifestyle modifications,
and, ultimately, joint replacement surgery. The Company believes that negatively reprogrammed macrophages may be key contributors to disease
severity in osteoarthritis and that the effective reprogramming of these negatively reprogrammed macrophages into their respective homeostatic
states may facilitate disease resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2024, the Company made
significant progress in its osteoarthritis clinical program, with a primary focus on the moderate to severe knee osteoarthritis trial.
This multi-center, multi-country, double-blinded, placebo-controlled Phase I/II trial aims to evaluate the efficacy and safety of Allocetra&trade;
in patients with moderate to severe knee osteoarthritis. Following the completion of the Phase I safety run-in stage, the Company announced
positive interim results, demonstrating statistically significant improvements in pain, functionality, and stiffness at both three- and
six-months post-treatment. The double-blind, randomized, placebo-controlled Phase II stage, which is statistically powered to assess the
efficacy of Allocetra&trade; injections into the knee at the highest dose of Allocetra&trade; used in the Phase I stage, is ongoing. In
April 2024, the Company completed the recruitment of the Phase II stage. Additionally, the Company is conducting trials in end-stage knee
osteoarthritis, basal thumb osteoarthritis, psoriatic arthritis, and temporomandibular joint osteoarthritis. All planned and expected
timelines for execution of clinical trials are subject to certain risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2024, the Company also
continued the development of its sepsis clinical program. In April 2024, the Company announced the 28-day topline data from the placebo-controlled,
randomized, dose-finding, multi-center Phase II trial evaluating Allocetra&trade; in patients with pneumonia-associated sepsis, which
was later expanded to include patients with sepsis resulting from biliary, urinary tract, or peritoneal infections. The 28-day topline
data stand-alone analysis demonstrated substantial reductions in sequential organ failure assessment scores and a 65% reduction in overall
mortality compared to expected mortality rates based on recently completed sizable clinical trials, particularly in patients with urinary
tract infection (&ldquo;UTI&rdquo;)-related sepsis. The 12-month follow-up analysis demonstrated a continued favorable safety profile,
as observed in the topline data, with no additional findings in the high-risk UTI-related sepsis group, as previously demonstrated in
the 28-day topline data. We are continuing to close down all active sites and complete all required operations to end as part of the trial&rsquo;s
finalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of market conditions,
the Company&rsquo;s limited cash availability and the substantial budget required for advancing to a follow-up clinical trial in patients
with sepsis, the Company, in lieu of internal development, plans to seek potential external collaboration or out-licensing opportunities
for the continued clinical development of Allocetra&trade; for use in patients with sepsis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain Information About Us In This Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were originally incorporated
on January 22, 2012 under the laws of the State of Israel as Bioblast Pharma Ltd. On March 26, 2019, we and Enlivex Therapeutics Ltd.
(n/k/a Enlivex Therapeutics R&amp;D Ltd., &ldquo;Enlivex R&amp;D&rdquo;), consummated a merger transaction whereby Enlivex R&amp;D merged
with one of our wholly owned subsidiaries, with Enlivex R&amp;D as the surviving entity in the merger. Upon consummation of the merger,
we changed our name to Enlivex Therapeutics Ltd. Our primary operating subsidiary, Enlivex R&amp;D, was originally incorporated in September
2005 under the laws of the State of Israel under the name Tolarex Ltd. In February 2010, Enlivex R&amp;D changed its name to Enlivex Therapeutics
Ltd., and, upon consummation of the merger described above, to Enlivex Therapeutics R&amp;D Ltd. In June 2021, Enlivex Therapeutics RDO
Ltd. was established in Israel as a wholly owned subsidiary. Our principal executive offices are located at 14 Einstein Street, Ness Ziona,
Israel 7403618 and our telephone number is: +972 26208072. Our wholly owned U.S. subsidiary, Enlivex Therapeutics Inc., incorporated in
Delaware, has been appointed our agent in the United States, and its registered address is 1811 Silverside Road, Wilmington, Delaware
19810. Our website address is https://www.enlivex.com. The information contained on, or that can be accessed through, our website is not
part of this prospectus. We have included our website address herein solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have appointed Cogency
Global Inc., which is located at 122 East 42nd Street, 18th Floor, New York, NY 10168, as our agent upon whom process may be served in
any action brought against us under the securities laws of the United States with an offering of securities registered by the registration
statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_005"></A>Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we specify otherwise
in the applicable prospectus supplement, we expect to use the net proceeds from the sale of the securities offered hereby for general
corporate purposes, which may include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">clinical, regulatory, manufacturing and research and development
activities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">potential acquisitions and in-licensing; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general corporate purposes.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any specific allocation of
the net proceeds of an offering of securities to a specific purpose will be determined at the time of such offering and will be described
in the related supplement to this prospectus.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_006"></A>Description of
Ordinary Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus describes
the general terms of our ordinary shares, which description is qualified in its entirety by reference to applicable Israeli law and the
terms and provisions contained in our amended and restated articles of association. When we offer to sell ordinary shares, we will describe
the specific terms of such offering in a supplement to this prospectus. Accordingly, for a description of the terms of a particular offering
of our ordinary shares, you must refer to both this prospectus and the applicable prospectus supplement. To the extent the information
contained in the prospectus supplement differs from this summary description, you should rely on the information contained in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our amended and restated
articles of association, the total number of shares of all classes of stock that we have authority to issue is 45,000,000 ordinary shares
with a par value of NIS 0.40 per share. As of December 31, 2024, there were 23,650,989 ordinary shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Rights, Preferences, Restrictions
of Shares and Shareholders Meetings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>General</I>. Our share capital is NIS 18,000,000 divided into 45,000,000 ordinary shares with a nominal value of NIS 0.40 each. Our ordinary shares may be certificated or uncertificated, subject to the Companies Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Voting</I>. The ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of ordinary shares that represent more than 50% of the voting power have the power to elect all the members of our board of directors the (&ldquo;Board of Directors&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Dividend and liquidation rights</I>. Our Board of Directors may declare a dividend to be paid to the holders of our ordinary shares according to their rights and interests in our profits and may fix the record date for eligibility and the time for payment, subject to the Israeli Companies Law 5759 1999 (the &ldquo;Companies Law&rdquo;). &nbsp;No unpaid dividend shall bear interest as against us. Our Board of Directors may determine that a dividend may be paid, wholly or partially, by the distribution of certain of our assets or by a distribution of paid up shares, debentures or debenture stock or any of our securities or of any other companies or in any one or more of such ways in the manner and to the extent permitted by the Companies Law. Our ordinary shares entitle each owner thereof to an equal right to participate in the distribution of the surplus assets of the Company in the event of our liquidation in accordance with the proportionate nominal value of the shares held thereby.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Transfer of shares; record dates</I>. Fully paid up ordinary shares may be freely transferred pursuant to our amended and restated articles of association unless such transfer is restricted or prohibited by another instrument or securities laws. Each shareholder who would be entitled to attend and vote at a general meeting of shareholders is entitled to receive notice of any such meeting. For purposes of determining the shareholders entitled to notice and to vote at such meeting, the Board of Directors will fix a record date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Voting; annual general and extraordinary meetings</I>. Subject to any rights or restrictions for the time being attached to any class or classes of shares, each shareholder shall have one vote for each share of which he, she or it is the holder. Our amended and restated articles of association do not permit cumulative voting and it is not mandated by Israeli law. Votes may be given either personally or by proxy. A proxy need not be a shareholder. If any shareholder is without legal capacity, he may vote by means of a trustee or a legal custodian, who may vote either personally or by proxy. If two or more persons are jointly entitled to a share then, in voting upon any question, the vote of the person whose name is registered first in the registry of shareholders as the owner of that share shall be accepted, whether in person or by proxy, and he, she or it is shall be entitled to vote such share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Quorum for general meeting</I>. The quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who holds or represent between them at least one-third of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time/date if so specified in the summons or notice of the meeting. At the reconvened meeting, any two or more shareholders present in person or by proxy shall constitute a lawful quorum.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Notice of general meeting</I>. Under the Companies Law, shareholder meetings generally require prior notice of not less than 21 days or, with respect to certain matters, such as election of directors and affiliated party transactions, not less than 35 days. Only shareholders of record as reflected on our share register at the close of business on the date fixed by the Board of Directors as the record date determining the then shareholders who will be entitled to vote, shall be entitled to notice of, and to vote, in person or by proxy, at a general meeting and any postponement or adjournment thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Annual; agenda; calling a general meeting</I>. An annual general meeting of shareholders is required to be held at least once in every calendar year (not later than 15 months after the holding of the last preceding annual general meeting), at such time and place as may be determined by the Board of Directors. At a general meeting, decisions shall be adopted only on matters that were specified on the agenda. The Board of Directors is obligated to call an extraordinary general meeting of the shareholders upon a written request in accordance with the Companies Law. The Companies Law provides that an extraordinary general meeting of shareholder may be called by the Board of Directors or by a request of two directors or 25% of the directors in office, or by shareholders holding at least 5% of the issued share capital of the company and at least 1% of the voting rights, or by shareholders holding at least 5% of the voting rights of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Majority vote</I>. Except as otherwise provided in the amended and restated articles of association or the Companies Law, any resolution at a general meeting shall be deemed adopted if approved by the holders of a majority of our voting rights represented at the meeting in person or by proxy and voting thereon. In the case of an equality of votes, the chairman of the meeting shall not be entitled to a casting vote.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Discrimination against shareholders</I>. There are no discriminating provisions in our amended and restated articles of association, against any existing or prospective holders of our ordinary shares as a result of a shareholder holding a substantial number of ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Modification of Class Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at any time, the share
capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issuance
of the shares of that class) may be varied with the consent in writing of the holders of all the issued shares of that class, or with
the sanction of a majority vote at a meeting of the shareholders passed at a separate meeting of the holders of the shares of that class.
The provisions of our amended and restated articles of association relating to general meetings shall apply, mutatis mutandis, to every
such separate class meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise provided by the conditions of
issuance, the enlargement of an existing class of shares, or the issuance of additional shares thereof, shall not be deemed to modify
or abrogate the rights attached to the previously issued shares of such class or of any other class. These conditions provide for the
minimum shareholder approvals permitted by the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restrictions on Shareholders Rights to Own Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association and the laws of the State of Israel do not restrict in any way the ownership or voting or our shares by non-residents of
Israel, except with respect to subjects of countries which are in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities Register</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registered with the
Israeli Registrar of Companies. Our registration number is 51-471648-9. Our amended and restated articles of association provide that
we may engage in any type of lawful business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that certain transactions, actions and arrangements be approved as provided for in a company&rsquo;s articles of association and in certain
circumstances by the Company&rsquo;s Audit Committee or the Company&rsquo;s Compensation Committee, by the Board of Directors itself and
by the shareholders. The vote required by the Audit Committee, Compensation Committee and the Board of Directors for approval of such
matters, in each case, is a majority of the disinterested directors participating in a duly convened meeting. If, however, a majority
of the members participating in such meeting have a personal interest in the approval of such matter, then all directors may participate
in the discussions and the voting on approval thereof and in such case the matter shall be subject to further shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder promptly disclose to the Company any personal interest that he or she may have and all related material information
or documents relating to any existing or proposed transaction by the Company. An interested office holder&rsquo;s disclosure must be made
promptly and in any event no later than the first meeting of the Board of Directors at which the transaction is considered. An office
holder is not obliged to disclose such information if the personal interest of the office holder derives solely from the personal interest
of his or her relative in a transaction that is not considered as an extraordinary transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;personal interest&rdquo;
is defined under the Companies Law to include the personal interest of a person in an action or in the business of a company, including
the personal interest of such person&rsquo;s relative or the interest of any corporation in which the person is an interested party, but
excluding a personal interest stemming solely from the fact of holding shares in such company. A personal interest furthermore includes
the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with respect to
his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal interest
in the approval of the matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
extraordinary transaction is defined as any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">a transaction other than in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">a transaction that is not on market terms; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">a transaction that may have a material impact on a company&rsquo;s profitability, assets or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If it is determined that an
office holder has a personal interest in a transaction that is not an extraordinary transaction, approval by the board of directors is
required for the transaction, unless the company&rsquo;s articles of association provide for a different method of approval. Approval
first by the company&rsquo;s Audit Committee and subsequently by the board of directors is required for an extraordinary transaction in
which an office holder has a personal interest. Further, so long as an office holder has disclosed his or her personal interest in a transaction,
the board of directors may approve an action by the office holder that would otherwise be deemed a breach of duty of loyalty. However,
a company may not approve a transaction or action that is adverse to the company&rsquo;s interest or that is not performed by the office
holder in good faith. Arrangements regarding the compensation, indemnification or insurance of an office holder require the approval of
the Compensation Committee, board of directors and, in certain circumstances, the shareholders, in that order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Israeli law, the
disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder
of a public company. In the context of a transaction involving a controlling shareholder or an officer who is a controlling shareholder
of the company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting rights if no other shareholder
holds more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval of the same transaction are
deemed to be a single shareholder and may be deemed a controlling shareholder for the purpose of approving such transaction. Extraordinary
transactions, including private placement transactions, with a controlling shareholder or in which a controlling shareholder has a personal
interest, and engagements with a controlling shareholder or his or her relative, directly or indirectly, including through a corporation
in his or her control, require the approval of the Audit Committee, the Board of Directors and the shareholders of the company, in that
order. In addition, the shareholder approval must fulfill one of the following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">at least a majority of the shares held by shareholders who do not have a personal interest in the transaction
and who are present and voting, in person, by proxy or by voting deed at the meeting, are voted in favor of the transaction (excluding
abstentions); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the votes of shareholders who have no personal interest in the transaction and who are present and voting,
in person, by proxy or by voting deed at the meeting, and who vote against the transaction may not represent more than two percent (2%)
of the voting rights of the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any such
transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years,
unless the Audit Committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Arrangements regarding the
terms of engagement and compensation of a controlling shareholder who is an office holder, and the terms of employment of a controlling
shareholder who is an employee of the company, require the approval of the Compensation Committee, Board of Directors and, generally,
the shareholders (by the same special majority described above), in that order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Israeli law, a
director who has a personal interest in an extraordinary transaction which is brought for discussion before our Board of Directors or
our Audit Committee shall neither vote in nor attend discussions concerning the approval of such transaction. If the director did vote
or attend as aforesaid, the approval given to the aforesaid activity or arrangement will be invalid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide that, subject to the Companies Law, our Board of Directors may delegate its authority, in whole or in part, to
such committees of the Board of Directors as it deems appropriate, and it may from time to time revoke such delegation. To the extent
permitted by the Companies Law, our Board of Directors may from time to time confer upon and delegate to a President, Chief Executive
Officer, Chief Operating Officer or other executive officer then holding office, such authorities and duties of the Board of Directors
as it deems fit, and they may delegate such authorities and duties for such period and for such purposes and subject to such conditions
and restrictions which they consider in our best interests, without waiving the authorities of the Board of Directors with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Arrangements regarding compensation
of directors require the approval of our Compensation Committee, our Board of Directors and the shareholders.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Acquisitions under Israeli
Law</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Full tender offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share
capital or of the issued and outstanding share capital of a certain class of shares is required by the Companies Law to make a tender
offer to all of the company&rsquo;s shareholders for the purchase of all of the issued and outstanding shares of the company or of all
of the issued and outstanding shares of the same class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the shareholders who do
not respond to or do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class of the shares, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of
the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer also
will be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition the Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If (a) the shareholders who
did not respond or accept the tender offer&nbsp;hold&nbsp;at&nbsp;least&nbsp;5%&nbsp;of the issued and outstanding share capital of the
company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not
have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or
more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the
company that will increase its holdings to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable
class from shareholders who accepted the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Special tender offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of at least 25% of the voting rights in the company. This rule does not apply if there is already
another holder of at least 25% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, the Companies Law
provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company
who holds more than 45% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These requirements do not
apply if the acquisition (i) occurs in the context of a private offering, on the condition that the shareholders meeting approved the
acquisition as a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no
person who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to give the acquirer 45%
of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a shareholder
holding at least 25% of the voting rights in the company and resulted in the acquirer becoming a holder of at least 25% of the voting
rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming
a holder of more than 45% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The special tender offer may
be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the
offeror and (ii) the special tender offer is accepted by a majority of the votes of those offerees who gave notice of their position in
respect of the offer; in counting the votes of offerees, the votes of a holder of control in the offeror, a person who has personal interest
in acceptance of the special tender offer, a holder of at least 25% of the voting rights in the company, or any person acting on their
or on the offeror&rsquo;s behalf, including their relatives or companies under their control, are not taken into account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability of the offer or shall
abstain from expressing any such opinion if it is unable to do so, provided that it gives the reasons for its abstention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An office holder in a target
company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing
or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders
for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds to believe he or she was
acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order
to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special tender offer
was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who did not respond to the special
offer or had objected to the special tender offer may accept the offer within four days of the last day set for the acceptance of the
offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is accepted, then the purchaser or any person or entity controlling it and any corporation controlled by them shall refrain
from making a subsequent tender offer for the purchase of shares of the target company and may not execute a merger with the target company
for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or
merger in the initial special tender offer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Merger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&rsquo;s Board of Directors and, unless certain requirements described under the Companies
Law are met, a majority of each party&rsquo;s shareholders, by a majority of each party&rsquo;s shares that are voted on the proposed
merger at a shareholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors of
a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable
concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors,
taking into account the financial condition of the merging companies. If the Board of Directors has determined that such a concern exists,
it may not approve a proposed merger. Following the approval of the Board of Directors of each of the merging companies, the Boards of
Directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of&nbsp;the shareholder
vote,&nbsp;unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding shares
or the right to appoint 25% or more of the directors of the other party, vote against the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction would have
been approved but for the separate approval of each class of shares or the exclusion of the votes of certain shareholders as provided
above, a court may still rule that the company has approved the merger upon the request of holders of at least 25% of the voting rights
of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal of the merging companies&rsquo;
value and the consideration offered to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, each
merging company must send a copy of the merger proposal to its secured creditors. Unsecured creditors are entitled to receive notice of
the merger, as provided by the regulations promulgated under the Companies Law. Upon the request of a creditor of either party to the
proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of
the merger, the surviving company will be unable to satisfy the obligations of the target company. The court may also give instructions
in order to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed with the Israeli
Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Potential Issues that Could Delay a Merger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain provisions of Israeli
corporate and tax law may have the effect of delaying, preventing or making more difficult any merger or acquisition of us.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Requirement of Disclosure
of Shareholder Ownership</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no provisions of
our amended and restated articles of association governing the ownership threshold above which shareholder ownership must be disclosed.
We are subject, however, to U.S. securities rules that require beneficial owners of more than 5% of our ordinary shares to make certain
filings with the SEC.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Changes in Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association do not impose any conditions governing changes in capital that are more stringent than required by the Companies Law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Listing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed
on the Nasdaq Capital Market under the symbol &ldquo;ENLV&rdquo; and on the Tel Aviv Stock Exchange under the symbol &ldquo;ENLV.&rdquo;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_007"></A>Description of
Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants to purchase
our ordinary shares. The warrants may be issued independently or together with ordinary shares offered by this prospectus and may be attached
to or separate from those ordinary shares. As of December 31, 2024, we had outstanding warrants to purchase an aggregate of up to 7,392,858
ordinary shares that we had offered and sold under our registration statement on Form F-3 declared effective on May 5, 2022 (Registration
No. 333-264561), which we refer to as our &ldquo;Outstanding Registered Warrants&rdquo;. Except to the extent set forth in the applicable
prospectus supplement, any warrants offered pursuant to this prospectus will be of a separate class and have different terms than the
Outstanding Registered Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the terms we have summarized
below will apply generally to any warrants we may offer under this prospectus, we will describe the particular terms of any warrants that
we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under a prospectus supplement
may differ from the terms we describe below, and you should refer to the applicable prospectus supplement for the specific terms of any
warrants that we offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue the warrants
under a warrant agreement, which we will enter into with a warrant agent to be selected by us. Each warrant agent will act solely as our
agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of
any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no
duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the
related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the ordinary
shares purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants in such
numerous distinct series as we determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will incorporate by reference
into the registration statement of which this prospectus forms a part the form of warrant agreement, including a form of warrant certificate,
that describes the terms of the series of warrants we are offering before the issuance of the related series of warrants. The following
summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference
to, all the provisions of the warrant agreement applicable to a particular series of warrants. We urge you to read the applicable prospectus
supplements related to the warrants that we sell under this prospectus, as well as the complete warrant agreements that contain the terms
of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in the applicable
prospectus supplement the terms of the warrants in respect of which this prospectus is being delivered, including, when applicable, the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the title of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the aggregate number of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the price or prices at which the warrants will be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the designation, terms and number of ordinary shares purchasable upon exercise of the warrants and procedures
by which such number may be adjusted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the date, if any, on and after which the warrants and the related ordinary shares will be separately transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the exercise price of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the dates or periods during which the warrants are exercisable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the minimum or maximum amount of the warrants that may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any terms relating to the modification of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the anti-dilution and adjustment of share capital provisions of the warrants, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any information with respect to book-entry procedures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the effect of any merger, consolidation, sale, or other disposition of our business on the warrant agreement
and the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any other terms of the warrants, including terms, procedures, and limitations relating to the transferability,
exchange, and exercise of such warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the material U.S. federal income tax consequences of holding or exercising the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any other specific terms, preferences, rights, or limitations of, or restrictions on, the warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any other specific terms of the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless specified in an applicable
prospectus supplement, warrants will be in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of warrant certificates
may exchange them for new certificates of different denominations, present them for registration of transfer, and exercise them at the
corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants
are exercised, holders of the warrants will not have any rights of holders of the underlying ordinary shares, including any rights to
receive dividends or to exercise any voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Registered Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ordinary shares registered
under the registration statement of which this prospectus is a part include those issuable upon exercise of the Outstanding Registered
Warrants, all of which we issued and sold on May 27, 2024 under our registration statement on Form F-3 (Registration No. 333-264531),
comprising up to (i) 3,571,429 ordinary shares issuable upon the exercise of certain Series A warrants exercisable at $1.40 per ordinary
share, which expire upon the earlier of 18 months following the issuance date and 60 days following our public announcement of positive
topline results from the ENX-CL-05-001 trial of Allocetra<SUP>TM</SUP>&nbsp;for the treatment of moderate-to-severe knee osteoarthritis,
(ii) 3,571,429 ordinary shares issuable upon the exercise of certain Series B warrants exercisable at $1.40 per ordinary share, which
expire upon the earlier of five and one-half years following the issuance date and 60 days following our public announcement of our filing
with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) for approval for Allocetra<SUP>TM</SUP>&rsquo;s osteoarthritis related
indication, (iii) 125,000 ordinary shares issuable upon the exercise of certain Series A placement agent warrants exercisable at $1.75
per ordinary share, which expire upon the earlier of 18 months following the issuance date and 60 days following our public announcement
of positive topline results from the ENX-CL-05-001 trial of Allocetra<SUP>TM</SUP>&nbsp;for the treatment of moderate-to-severe knee osteoarthritis,
and (iv) 125,000 ordinary shares issuable upon the exercise of certain Series B placement agent warrants exercisable at $1.75 per ordinary
share, which expire upon the earlier of five years following the commencement of the sale of the securities offered thereby and 60 days
following our public announcement of our filing with the FDA for approval for&nbsp;Allocetra<SUP>TM</SUP>&rsquo;s&nbsp;osteoarthritis
related indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_008"></A>Description of
Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description,
together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions
of the units that we may offer under this prospectus. Units may be offered independently or together with ordinary shares and warrants
offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below
will generally apply to any units that we may offer under this prospectus, we will describe the particular terms of any series of units
that we may offer in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement
may differ from the terms described below, and you should refer to the applicable prospectus supplement for the specific terms of any
units that we offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will incorporate by reference
into the registration statement of which this prospectus forms a part the form of unit agreement, including a form of unit certificate,
if any, that describes the terms of the series of units we are offering before the issuance of the related series of units. The following
summaries of material provisions of the units and the unit agreements are subject to, and qualified in their entirety by reference to,
all the provisions of the unit agreement applicable to a particular series of units. We urge you to read the applicable prospectus supplements
related to the units that we sell under this prospectus, as well as the complete unit agreements that contain the terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units consisting
of ordinary shares and warrants. Each unit will be issued so that the holder of the unit is also the holder of each security included
in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each security included in the unit. The unit
agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately,
at any time, or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplement the terms of the series of units, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the designation and terms of the units and of the securities comprising the units, including whether and
under what circumstances those securities may be held, traded or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any material provisions of the governing unit agreement that differ from those described below; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities
comprising the units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions described in
this section, as well as those described under &ldquo;Description of Ordinary Shares&rdquo; and &ldquo;Description of Warrants,&rdquo;
will apply to each unit and to any ordinary share or warrant included in each unit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuance in Series </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units in such
amounts and in such numerous distinct series as we determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights by Holders of Units </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each unit agent, if any, will
act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with
any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have
no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit, without the consent of the related
unit agent or the holder of any other unit, may enforce by appropriate legal action its rights as holder under any security included in
the unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Title </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, the unit agent, and any
of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate
for any purposes and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_009"></A>Taxation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The material Israeli and U.S.
federal income tax consequences relating to the purchase, ownership and disposition of any of the securities offered by this prospectus
will be set forth in the prospectus supplement offering those securities or incorporated by reference from our Annual Report on Form 20-F
or other public filings we make with the SEC.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_010"></A>Plan of Distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
offered hereby from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of
these methods. We may sell the securities (1) to or through underwriters or dealers (acting as principal or agent), (2) through agents
and/or (3)&nbsp;directly to one or more purchasers. We may distribute the securities from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at a fixed price or prices, which may be changed;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at market prices prevailing at the time of sale;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at prices related to such prevailing market prices;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at negotiated prices; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">in sales &ldquo;at the market&rdquo;, within the meaning of
Rule 415(a)(4) of the Securities Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may directly solicit offers
to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase the securities
from time to time. We will name in a prospectus supplement any agent involved in the offer or sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we utilize a dealer in
the sale of the securities being offered by this prospectus, we will sell the securities to the dealer, as principal. The dealer may then
resell the securities to the public at varying prices to be determined by the dealer at the time of resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we utilize an underwriter
in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the
time of sale and provide the name of any underwriter in the prospectus supplement that the underwriter will use to make resales of the
securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the underwriter
may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities
to or through dealers, and the underwriter may compensate those dealers in the form of discounts, concessions or commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide in the applicable
prospectus supplement any compensation we pay to underwriters, dealers or agents in connection with the offering of the securities, and
any discounts, concessions or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating
in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;), and any discounts and commissions received by them and any profit realized by them on resale of the securities
may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents
against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in
respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An underwriter may engage
in over-allotment, stabilizing transactions, short covering transactions and penalty bids in accordance with securities laws. Over-allotment
involves sales in excess of the offering size, which creates a short position. Stabilizing transactions permit bidders to purchase the
underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of
the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to
reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to
cover short positions. Those activities may cause the prices of the securities to be higher than they would otherwise be. The underwriters
may engage in these activities on any exchange or other market in which the securities may be traded. If commenced, the underwriters may
discontinue these activities at any time. The effect of these transactions may be to stabilize or maintain the market price of the securities
at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters, dealers
and agents may engage in transactions with us, or perform services for us, in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_011"></A>Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the expenses (other than underwriting discounts and commissions or agency fees and other items constituting underwriters&rsquo; or agents&rsquo;
compensation, if any) expected to be incurred by us in connection with a possible offering of securities registered under this registration
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC Registration Fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1,196.48</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Blue Sky Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer Agent Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">*</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">*</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">To be provided by a prospectus supplement or a Report on
Form 6-K that is incorporated by reference into this prospectus.</TD>
</TR></TABLE>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_012"></A>Legal Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered hereby will be passed upon for us by FISCHER (FBC &amp; Co.) and Greenberg Traurig P.A.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_013"></A>Experts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements included in our Annual Report on Form 20-F for the year ended December 31, 2024 are incorporated herein by reference in reliance
on the report of Yarel + Partners, an independent registered public accounting firm, given on the authority of such firm as an expert
in accounting and auditing.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_014"></A>Enforceability
of Civil Liabilities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel. Service of process upon us and upon our directors and officers and any Israeli experts named in this
registration statement, most of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore,
because substantially all of our assets and most of our directors and officers are located outside of the United States, any judgment
obtained in the United States against us or certain of our directors and officers may be difficult to collect within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been informed by our
legal counsel in Israel, FISCHER (FBC &amp; Co.), that it may be difficult to assert U.S. securities law claims in original actions instituted
in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws on the grounds that Israel
is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine
that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law
must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure will also
be governed by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to specified time
limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which (subject to limited exceptions)
is non-appealable, including a judgment based upon the civil liability provisions of the Securities Act or the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and including a monetary or compensatory judgment in a non-civil matter, provided
that, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the judgment was rendered by a court which was, according to the laws of the state of the court, competent
to render the judgment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability
of judgments in Israel and the substance of the judgment is not contrary to public policy; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the judgment is executory in the state in which it was given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Even if these conditions
are met, an Israeli court may not declare a foreign civil judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the judgment was obtained by fraud;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable
in the opinion of the Israeli court;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the judgment was rendered by a court not competent to render such judgement according to the laws of private
international law as they apply in Israel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the judgment is contradictory to another judgment that was rendered in the same matter between the same
parties and that is still valid; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">at the time the action was brought in the foreign court, a lawsuit in the same matter and between the
same parties was pending before a court or tribunal in Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a foreign judgment is enforced
by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred
out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli
court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment,
but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated
in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli
regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_015"></A>Where You Can Find
More Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual reports on
Form 20-F, reports on Form 6-K, and other information with the SEC under the Exchange Act. The SEC maintains an Internet site that contains
reports and other information that we file electronically with the SEC and which are available at the SEC&rsquo;s website at http://<I>www.sec.gov</I>.
In addition, we maintain an Internet website at <I>www.enlivex.com</I>. Information contained on or accessible through our website is
not incorporated into or made a part of this prospectus or the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the SEC. The registration statement contains more information than this prospectus regarding
us and our securities, including certain exhibits. You can obtain a copy of the registration statement from the SEC at the address listed
above or from the SEC&rsquo;s website listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_016"></A>Incorporation of
Certain Documents by Reference</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it, which means that we can disclose important information to you by referring to those
documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with
the SEC will automatically update, modify and supersede this information. We incorporate by reference the following documents we have
filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm">Form
20-F</A> for the year ended December 31, 2024, filed with the SEC on April 30, 2025; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000114420414045171/v384900_8a12b.htm">Form
8-A</A> filed with the SEC on July 28, 2014, in which there is described the terms, rights and provisions applicable to the shares of
the Company&rsquo;s ordinary shares, including any amendment or report filed for the purpose of updating such description, including
the description of ordinary shares filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019ex2-1_enlivex.htm">Exhibit
2.1</A> to the Company&rsquo;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019_enlivextherap.htm">Form
20-F</A> filed April 30, 2020.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All annual reports on Form
20-F we file with the SEC pursuant to the Exchange Act after the date of this prospectus and prior to termination or expiration of this
registration statement shall be deemed incorporated by reference into this prospectus and to be part hereof from the date of filing of
such documents. We may incorporate by reference any Form 6-K subsequently submitted to the SEC by identifying in such Form 6-K that it
is being incorporated by reference into this prospectus (including any such Form 6-K that we submit to the SEC after the date of the filing
of the registration statement of which this prospectus forms a part and prior to the date of effectiveness of such registration statement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statements made in this
prospectus or in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed to be modified or
superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed
document that is also incorporated or deemed to be incorporated by reference in this prospectus modifies or supersedes the statement.
Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide without charge
to each person, including any shareholder, to whom a prospectus is delivered, upon written or oral request of that person, a copy of any
and all of the information incorporated by reference into this prospectus. Please direct requests to us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Attention: Shachar Shlosberger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">14 Einstein Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Nes Ziona</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Israel 7403618</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Tel: +972.2.6708072</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exhibits to the filings will
not be sent, however, unless those exhibits have specifically been incorporated by reference in such filings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ENLIVEX THERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="image_002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="color: Red">The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are
not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUBJECT TO COMPLETION, DATED MAY 2, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Prospectus<BR>
&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to 8,800,000 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On December 30, 2022, we entered into a sales agreement (the &ldquo;Sales
Agreement&rdquo;), with Cantor Fitzgerald &amp; Co. and Citizens JMP Securities, LLC, as agents (each an &ldquo;Sales Agent&rdquo; and
together the &ldquo;Sales Agents&rdquo;), relating to the sale of our ordinary shares, par value NIS 0.40 per share (&ldquo;ordinary shares&rdquo;).&nbsp;In
accordance with the terms of the&nbsp;Sales Agreement,&nbsp;we may elect to sell up to 8,800,000 ordinary shares&nbsp;under this prospectus
from time to time through the Sales Agents. However, we are not obligated to sell any shares pursuant to the Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we elect to sell any shares
pursuant to&nbsp;this prospectus,&nbsp;such sales, if any, may be made in transactions that are deemed to be &ldquo;at-the-market&rdquo;
offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), including sales
made directly on or through the Nasdaq Capital Market, the existing trading market for our ordinary shares, or any other existing trading
market in the United States for our ordinary shares, sales made to or through a market maker other than on an exchange or otherwise, directly
to either Sales Agent as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to
such prevailing market prices, or in any other method permitted by law, which may include block trades.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we elect to sell any shares
pursuant to the Sales Agreement, the Sales Agents are not required to sell any specific amount, but will act as our sales agents using
commercially reasonable efforts consistent with their normal trading and sales practices. There is no arrangement for funds to be received
in any escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we elect to sell any ordinary
shares pursuant to this prospectus, we will pay the Sales Agents, in the aggregate, a total commission equal to 3.0% of the gross sales
price per ordinary share issued by us and sold through either Agent. In connection with the any future sales of the ordinary shares on
our behalf, each Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the compensation
of such Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution
to the Sales Agents with respect to certain liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed
on the Nasdaq Capital Market under the symbol &ldquo;ENLV&rdquo; and on the Tel Aviv Stock Exchange under the symbol &ldquo;ENLV.&rdquo;
The last reported sale price of our ordinary shares on the Nasdaq Capital Market on May 1, 2025 was $1.05 per share. The last reported
sale price of our ordinary shares on the Tel Aviv Stock Exchange on April 30, 2025 was NIS 3.693 or $1.02 per share (based on the exchange
rate reported by the Bank of Israel on the same day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of May 1, 2025, the aggregate
market value of our outstanding ordinary shares held by non-affiliates was approximately $27,756,152 based on 23,849,935 outstanding ordinary
shares as of March 31, 2025, of which approximately 22,750,944 ordinary shares were held by non-affiliates. Pursuant to General Instruction
I.B.5 of Form F-3, in no event may we offer securities pursuant to this prospectus with an aggregate offering price of more than one-third
of the aggregate market value of our ordinary shares held by non-affiliates in any 12-month period, or approximately $9,252,050, for as
long as the aggregate market value of our ordinary shares held by non-affiliates is less than $75,000,000. We have not offered any of
our securities pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on, and includes,
the date of this prospectus. Based on a price of $1.05 per share, which was the closing price of our ordinary shares as reported on the
Nasdaq Capital Market on May 1, 2025, the aggregate offering price of the 8,800,000 ordinary shares offered hereby is within the limitation
set forth under General Instruction I.B.5 of Form F-3, and, for so long as we are subject to such limitation, we will not sell ordinary
shares with an aggregate market value in excess of $9,252,050 in any 12 calendar-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If, subsequent to the date
of this prospectus, the aggregate market value of our outstanding ordinary shares held by non-affiliates equals or exceeds $75,000,000,
then the one-third limitation on sales will not apply to additional sales made pursuant to this prospectus or any related prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves a high degree of risk. See the risks described in the &ldquo;Risk Factors&rdquo; section on page S-4 of this prospectus
and in the reports we file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) pursuant to the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;), incorporated by reference into this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>Neither the SEC the Israel
Securities Authority nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or
adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Cantor</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Citizens Capital Markets</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; text-decoration: none; width: 100%">
  <TR STYLE="text-decoration: none; vertical-align: bottom">
    <TD STYLE="text-decoration: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-decoration: none; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-decoration: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-decoration: none"><B>Page</B></FONT></P>

</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none; width: 90%"><A HREF="#s_001">About This Prospectus</A></TD>
    <TD STYLE="text-decoration: none; text-align: center; width: 10%">S-ii</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_002">Prospectus Summary</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-1</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><A HREF="#s_003">The Offering</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-3</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_004">Risk Factors</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-4</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><A HREF="#s_005">Cautionary Note Regarding Forward-Looking Statements</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-8</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_006">Use of Proceeds</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-10</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><A HREF="#s_007">Capitalization</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-11</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_008">Dilution</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-12</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><A HREF="#s_009">Description of Ordinary Shares</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-13</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_010">Plan of Distribution</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-20</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><A HREF="#s_011">Legal Matters</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-21</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_012">Experts</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-21</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none"><A HREF="#s_013">Where You Can Find More Information</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-21</TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none"><A HREF="#s_014">Incorporation of Certain Documents by Reference</A></TD>
    <TD STYLE="text-decoration: none; text-align: center">S-22</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All references to the terms
the &ldquo;Company,&rdquo; &ldquo;Enlivex,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; in this prospectus refer to
Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, and its consolidated subsidiaries, unless the context
requires otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All references to &ldquo;$&rdquo;
and &ldquo;U.S. Dollars&rdquo; are to United States dollars and all references to &ldquo;NIS&rdquo; are to New Israeli Shekels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus is part of a
registration statement that we filed with the SEC, using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process,
we may from time to time sell ordinary shares, warrants or units comprising any combination of these securities, in one or more offerings
up to a total dollar amount of $300,000,000. Under this prospectus, we may from time to time offer and sell up to 8,800,000 ordinary
shares at prices and on terms to be determined by market conditions at the time of the offering. The 8,800,000 ordinary shares that may
be sold under this prospectus are included in the $300,000,000 of securities that may be sold under the registration statement. However,
pursuant to General Instruction I.B.5 of Form F-3, in no event may we offer securities pursuant to this prospectus with an aggregate
offering price of more than one-third of the aggregate market value of our ordinary shares held by non-affiliates, or $9,252,050, in
any 12-month period, for as long as the aggregate market value of our ordinary shares held by non-affiliates is less than $75,000,000.
Based on a price of $1.05 per share, which was the closing price of our ordinary shares as reported on the Nasdaq Capital Market on May
1, 2025, the aggregate offering price of the 8,800,000 ordinary shares offered hereby is within the limitation set forth under General
Instruction I.B.5 of Form F-3, and, for so long as we are subject to such limitation, we will not sell ordinary shares with an aggregate
market value in excess of $9,252,050 in any 12 calendar-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As permitted by the rules
and regulations of the SEC, the registration statement, of which this prospectus forms a part, includes additional information not contained
in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&rsquo;s website or at
the SEC&rsquo;s offices described below under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Documents by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have not, and the Sales
Agents have not, authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus
and any related free writing prospectus filed by us with the SEC. Neither we nor the Sales Agents authorized any person to provide you
with different or additional information. If anyone provides you with different or additional information, you should not rely on it.
We take no responsibility for, and provide no assurance as to the reliability of any other information that others may give you. This
prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described
in this prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer
or solicitation is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">You should not assume that
the information in this prospectus or any documents we incorporate by reference herein or therein is accurate as of any date other than
the respective dates on the front cover of those documents. Our business, financial condition, results of operations and prospects may
have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">You should also carefully
read and consider the information in the documents to which we have referred you in the sections entitled &ldquo;Where You Can Find More
Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference&rdquo; in this prospectus.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><I>The following summary
of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus and in the
documents we incorporate by reference. Because this is only a summary, it does not contain all of the information that may be important
to you. You should carefully read this prospectus, including the documents incorporated by reference, which are identified under &ldquo;Incorporation
of Certain Documents by Reference&rdquo; in this prospectus. You should also carefully consider the matters discussed in the section in
this prospectus entitled &ldquo;Risk Factors&rdquo;, in our Annual Report on Form 20-F for the year ended December 31, 2024 and in other
documents incorporated herein by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Company is a clinical-stage
macrophage reprogramming immunotherapy company, developing Allocetra<SUP>TM</SUP>, a universal, off-the-shelf cell therapy designed to
reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for
immune system rebalancing and resolution of debilitating and life-threatening conditions. Non-homeostatic macrophages contribute significantly
to the severity of a given disease. By restoring macrophage homeostasis, Allocetra&trade; has the potential to provide a novel immunotherapeutic
mechanism of action for debilitating and life-threatening clinical indications that are defined as &ldquo;unmet medical needs,&rdquo;
as a stand-alone therapy or in combination with leading therapeutic agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Macrophages are tissue-resident
or infiltrating immune cells critical for innate immunity, normal tissue development, and repair of damaged tissue. Macrophages&rsquo;
function is a result of their original designation, their local micro-environment, and the type of metabolites, substances or pathogens
to which they are exposed. When reprogrammed out of their homeostatic state, macrophages contribute to the pathophysiology of multiple
inflammatory diseases, including osteoarthritis, sepsis and various inflammatory disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We believe the Company&rsquo;s
primary innovative immunotherapy, Allocetra<SUP>TM</SUP>, represents a paradigm shift in macrophage reprogramming, moving from targeting
a specific subset of macrophages or a specific pathway affecting macrophage activity, to a fundamental view of macrophage homeostasis.
Restoring macrophage homeostasis may induce the immune system to rebalance itself to normal levels of operation, thereby promoting disease
resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Company is focused on
osteoarthritis as its main chronic inflammatory indication. Osteoarthritis is a degenerative disease, characterized by low-grade inflammation,
that affects more than 32.5 million people in the United States. Treatment of osteoarthritis represents a substantial unmet medical need,
particularly non-invasive treatments, as current therapeutic options are largely limited to pain management, lifestyle modifications,
and, ultimately, joint replacement surgery. The Company believes that negatively reprogrammed macrophages may be key contributors to disease
severity in osteoarthritis and that the effective reprogramming of these negatively reprogrammed macrophages into their respective homeostatic
states may facilitate disease resolution.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In 2024, the Company made
significant progress in its osteoarthritis clinical program, with a primary focus on the moderate to severe knee osteoarthritis trial.
This multi-center, multi-country, double-blinded, placebo-controlled Phase I/II trial aims to evaluate the efficacy and safety of Allocetra&trade;
in patients with moderate to severe knee osteoarthritis. Following the completion of the Phase I safety run-in stage, the Company announced
positive interim results, demonstrating statistically significant improvements in pain, functionality, and stiffness at both three- and
six-months post-treatment. The double-blind, randomized, placebo-controlled Phase II stage, which is statistically powered to assess the
efficacy of Allocetra&trade; injections into the knee at the highest dose of Allocetra&trade; used in the Phase I stage, is ongoing. In
April 2024, the Company completed the recruitment of the Phase II stage. Additionally, the Company is conducting trials in end-stage knee
osteoarthritis, basal thumb osteoarthritis, psoriatic arthritis, and temporomandibular joint osteoarthritis. All planned and expected
timelines for execution of clinical trials are subject to certain risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">During 2024, the Company also
continued the development of its sepsis clinical program. In April 2024, the Company announced the 28-day topline data from the placebo-controlled,
randomized, dose-finding, multi-center Phase II trial evaluating Allocetra&trade; in patients with pneumonia-associated sepsis, which
was later expanded to include patients with sepsis resulting from biliary, urinary tract, or peritoneal infections. The 28-day topline
data stand-alone analysis demonstrated substantial reductions in sequential organ failure assessment scores and a 65% reduction in overall
mortality compared to expected mortality rates based on recently completed sizable clinical trials, particularly in patients with urinary
tract infection (&ldquo;UTI&rdquo;)-related sepsis. The 12-month follow-up analysis demonstrated a continued favorable safety profile,
as observed in the topline data, with no additional findings in the high-risk UTI-related sepsis group, as previously demonstrated in
the 28-day topline data. We are continuing to close down all active sites and complete all required operations to end as part of the trial&rsquo;s
finalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In light of market conditions,
the Company&rsquo;s limited cash availability and the substantial budget required for advancing to a follow-up clinical trial in patients
with sepsis, the Company, in lieu of internal development, plans to seek potential external collaboration or out-licensing opportunities
for the continued clinical development of Allocetra&trade; for use in patients with sepsis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We were originally
incorporated on January 22, 2012 under the laws of the State of Israel as Bioblast Pharma Ltd. On March 26, 2019, we and Enlivex Therapeutics
Ltd. (n/k/a Enlivex Therapeutics R&amp;D Ltd., &ldquo;Enlivex R&amp;D&rdquo;), consummated a merger transaction whereby Enlivex R&amp;D
merged with one of our wholly owned subsidiaries, with Enlivex R&amp;D as the surviving entity in the merger. Upon consummation of the
merger, we changed our name to Enlivex Therapeutics Ltd. Our primary operating subsidiary, Enlivex R&amp;D, was originally incorporated
in September 2005 under the laws of the State of Israel under the name Tolarex Ltd. In February 2010, Enlivex R&amp;D changed its name
to Enlivex Therapeutics Ltd., and, upon consummation of the merger described above, to Enlivex Therapeutics R&amp;D Ltd. In June 2021,
Enlivex Therapeutics RDO Ltd. was established in Israel as a wholly owned subsidiary. Our principal executive offices are located at 14
Einstein Street, Ness Ziona, Israel 7403618 and our telephone number is: +972 26208072.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_003"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares Offered by Us</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 8,800,000 ordinary shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares to be Outstanding after this Offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 32,450,989 additional ordinary shares may be outstanding following consummation of this offering, assuming the sale of 8,800,000 ordinary shares. The actual number of ordinary shares issued will depend on whether and to what extent we elect to sell shares pursuant to this prospectus. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan of Distribution</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sales Agents may, according to the terms of the Sales Agreement, sell the ordinary shares offered under this prospectus in an &ldquo;at-the-market&rdquo; offering as defined in Rule 415(a)(4) under the Securities Act. Each Sales Agent has agreed to use commercially reasonable efforts consistent with its normal trading and sales practices to make sales of the ordinary shares offered hereby. See &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of Proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from this offering
    for (i) clinical, regulatory, manufacturing and research and development activities; (ii) potential acquisitions and in-licensing; and
    (iii) other general corporate purposes. See &ldquo;Use of Proceeds&rdquo; for additional information.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities involves risks. You should read carefully the &ldquo;Risk Factors&rdquo; section of this prospectus beginning on page S-4 and in the documents incorporated by reference for a discussion of factors that you should carefully consider before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq Capital Market Symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ENLV&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel Aviv Stock Exchange Symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ENLV&rdquo;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The number of shares to be
outstanding after this offering above is based on our actual ordinary shares outstanding as of December 31, 2024 and excludes, in each
case as of December 31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,898,015 options held by our employees, directors and consultants
to purchase ordinary shares under the Company&rsquo;s equity compensation plans at a weighted average exercise price of $5.37 per share,
of which 2,315,048 options were exercisable as of December 31, 2024, at a weighted average exercise price of $5.46 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,234,572 ordinary shares issuable upon vesting of restricted
stock units held by our employees and directors under our Global Share Incentive Plan (2019), referred to as the &ldquo;2019 Plan&rdquo;;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,121,494 ordinary shares available for future issuance under
the 2019 Plan as of December 31, 2024; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">7,645,109 ordinary shares issuable upon exercise of warrants
at a weighted average exercise price of $2.007 per share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all information in this prospectus assumes no vesting of restricted stock units or exercise of outstanding options or warrants described
above.&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><I>Investing in our securities
involves a high degree of risk.&nbsp;You should consider carefully the risks and uncertainties described below, the risks described under
the heading &ldquo;Risk Factors&rdquo; in our Annual Report on Form 20-F for the year ended December 31, 2024, which is incorporated by
reference in this prospectus, and under similar headings in our subsequently filed reports on Form 6-K, and other information contained
in or incorporated by reference in this prospectus, including our audited consolidated financial statements and the related notes, as
well as our unaudited condensed consolidated financial statements and the related notes, before you decide whether to purchase our securities.
If any of the following risks actually occur, our business, financial condition, results of operations, cash flow and prospects could
be materially and adversely affected. As a result, the trading price of our ordinary shares could decline and you could lose all or part
of your investment in our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>We do not know whether a market for our
ordinary shares will be sustained or what the market price of our ordinary shares will be and as a result it may be difficult for you
to sell your shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The trading price of our ordinary
shares has been and is likely to remain volatile. The following factors, some of which are beyond our control, in addition to other risk
factors described in this section and in our Annual Report on Form 20-F for the year ended December 31, 2024, which is incorporated by
reference in this prospectus, may have a significant impact on the market price of our ordinary shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">inability to obtain the approvals necessary to commence further clinical trials;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">unsatisfactory results of clinical trials;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">announcements of therapeutic innovations or new products by us or our competitors;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">changes or developments in laws or regulations applicable to our product candidates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any adverse changes to our relationship with manufacturers or suppliers;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any product liability actions or intellectual property infringement actions in which we may become involved;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">announcements concerning our competitors or the pharmaceutical or biotechnology industries in general;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">achievement of expected product sales and profitability or our failure to meet expectations;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our commencement of, or involvement in, litigation;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any major changes in our board of directors, management or other key personnel;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">legislation in the United States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">expiration or terminations of licenses, research contracts or other collaboration agreements;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">public concern as to the safety of therapeutics we, our licensees or others develop;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">success of research and development projects;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">variations in our and our competitors&rsquo; results of operations;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">developments by our licensees, if any; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">future issuances of ordinary shares or other securities; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">general political, economic and market conditions, including the war between Israel and Hamas.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">These factors may materially
and adversely affect the market price of our ordinary shares, which could result in substantial losses by our investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, the stock market
in general, and the Nasdaq Capital Market and the market for biotechnology companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies like ours. Broad market
and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating performance. Further,
a systemic decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.
The price volatility of our ordinary shares might be worse if the trading volume of our ordinary shares is low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Moreover, the liquidity of
our ordinary shares is limited. Among other factors, the number of ordinary shares that can be bought and sold at a given price may result
in lower prices for our ordinary shares and a larger spread between the bid and ask prices therefor. In addition, without a large float,
our ordinary shares are less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of
our ordinary shares may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate its
investment in our ordinary shares. Trading of a relatively small volume of our ordinary shares may have a greater impact on the trading
price of our shares than would be the case if our public float were larger. We cannot predict the prices at which our ordinary shares
will trade in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B><I>Management will have broad discretion as to the use of the net
proceeds from this offering, and we may not use the proceeds effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our management will have broad
discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated
at the time of this offering, as described in &ldquo;Use of Proceeds&rdquo;. Our shareholders may not agree with the manner in which our
management chooses to allocate and spend the net proceeds from this offering. Moreover, our management may use the net proceeds from this
offering for corporate purposes that may not increase our market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>You will experience immediate dilution.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
offering price for the ordinary shares offered pursuant to this prospectus is higher than the net tangible book value of each
outstanding share of our ordinary shares. Purchasers of ordinary shares in this offering will experience immediate dilution on a
book value basis. Following this offering, there will be an immediate increase in net tangible book value of approximately $0.0013
per share to our existing shareholders, and an immediate dilution of $0.0514 per share to new investors purchasing shares in this
offering, assuming that an aggregate of 8,800,000 ordinary shares are sold at a public offering price of $1.05 per share, the last
reported sale price of our ordinary shares on the Nasdaq Capital Market on May 1, 2025 for aggregate gross proceeds of approximately
$9,240,000, and after deducting estimated commissions and estimated offering expenses payable by us. If the holders of outstanding
options or other securities convertible into our ordinary shares exercise those options or other such securities at prices below the
offering price, you will incur further dilution. Please see the section in the prospectus entitled &ldquo;<I>Dilution</I>&rdquo; for
a more detailed discussion of the dilution you will incur in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>If we raise additional capital in the future,
your ownership in us could be diluted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we may at any time, including during this offering, offer additional ordinary shares or other securities convertible into or
exchangeable for our ordinary shares at prices that may not be the same as the price per ordinary share in this offering. We may sell
ordinary shares or other securities in any other offering at a price per ordinary share that is less than the price per ordinary share
paid by investors in this offering, and investors purchasing ordinary shares or other securities in the future could have rights superior
to existing shareholders, including investors who purchase ordinary shares in this offering pursuant to sales by us under the Sales Agreement.
The price per share at which we sell additional ordinary shares or securities convertible into ordinary shares in future transactions
may be higher or lower than the price per ordinary share in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Sales of a substantial number of our ordinary
shares, or the perception that such sales might occur, could adversely affect the trading price of our ordinary shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, we
had 23,650,989 ordinary shares outstanding, excluding ordinary shares issuable upon exercise of outstanding warrants and shares that are
issuable under our existing equity compensation plans. In addition, we may issue and sell additional ordinary shares in the public markets,
including under this prospectus. Sales of a substantial number of our ordinary shares in the public markets, including during this offering,
or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our
ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional
ordinary shares or other equity securities and could result in a decline in the value of your investment in our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Our ordinary shares are listed in two markets
and this may result in price variations that could affect the trading price of our ordinary shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed
on the Nasdaq Capital Market and the Tel Aviv Stock Exchange, both under the symbol &ldquo;ENLV.&rdquo; Trading in our ordinary shares
on these markets is made in different currencies (U.S. Dollars on the Nasdaq Capital Market and New Israeli Shekels on the Tel Aviv Stock
Exchange), and at different times (due to the different time zones, different trading days and different public holidays in the United
States and Israel). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease
in the trading price of our ordinary shares on one of these markets could cause a decrease in the trading price of our ordinary shares
on the other market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>The ordinary shares offered hereby will
be sold in &ldquo;at-the-market&rdquo; offerings, and investors who buy ordinary shares at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Investors who purchase ordinary
shares under this prospectus at different times will likely pay different prices, and so may experience different levels of dilution and
different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers
of ordinary shares sold in this offering, and there is no minimum or maximum sales price for shares to be sold in this offering. Investors
may experience a decline in the value of the ordinary shares they purchase in this offering as a result of sales made at prices lower
than the prices they paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>The actual number of ordinary shares we
will issue under the Sales Agreement, at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject to certain limitations
in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a sales notice to a Sales Agent at any time
throughout the term of the Sales Agreement. The number of ordinary shares that are sold by a Sales Agent after delivering a sales notice
will fluctuate based on the market price of the ordinary shares during the sales period and limits we set with such Sales Agent. Because
the price per ordinary share of each ordinary share sold will fluctuate based on the market price of our ordinary shares during the sales
period, it is not possible at this stage to predict the number of ordinary shares that will be ultimately issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Because we do not intend to declare cash
dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of our ordinary shares
for any return on their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings, if any, for the development,
operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result,
capital appreciation, if any, of our ordinary shares will be your sole source of gain for the foreseeable future. Consequently, in the
foreseeable future, you will likely only experience a gain from your investment in our ordinary shares if the price of our ordinary shares
increases beyond the price in which you originally acquired the ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_005"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
prospectus contains &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995
and other U.S. Federal securities laws. These forward-looking statements include, but are not limited to</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our expectations regarding the timing of clinical trials with respect to Allocetra&trade;;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our expectations regarding the progress of our clinical trials, including the duration, cost and whether such trials will be conducted at all;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our intention to successfully complete clinical trials in order to be in a position to submit applications for accelerated regulatory paths in the EU and the United States;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the possibility that we will apply in the future for regulatory approval for our current and any future product candidates we may develop, and the costs and timing of such regulatory approvals;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the likelihood of regulatory approvals for any product candidate we may develop;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the timing, cost or other aspects of the commercial launch of any product candidate we may develop, including the possibility that we will build a commercial infrastructure to support commercialization of our current and any future product candidates we may develop;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">future sales of our product candidates or any other future products or product candidates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to achieve favorable pricing for our product candidates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the potential for our product candidates to receive orphan drug designations;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">that any product candidate we develop potentially offers effective solutions for various diseases;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">whether we will develop any future product candidates internally or through strategic partnerships;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our expectations regarding the manufacturing and supply of any product candidate for use in our clinical trials, and the commercial supply of those product candidates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">third-party payer reimbursement for our current or any future product candidates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our estimates regarding anticipated expenses, capital requirements and our needs for substantial additional financing;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">patient market sizes and market adoption of our current or any future product candidates by physicians and patients;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">completion and receiving favorable results of clinical trials for our product candidates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">protection of our intellectual property, including issuance of patents to us by the United States Patent and Trademark Office, and other governmental patent agencies;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our intention to pursue marketing and orphan drug exclusivity periods that are available to us under regulatory provisions in certain countries;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the development and approval of the use of our current or any future product candidates for any indication;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our expectations regarding commercial and pre-commercial activities;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our expectations regarding collaborations, licensing, acquisitions, and strategic operations; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">our liquidity; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the impact of the economic, public health, political and security situation in Israel, the U.S. and other countries in which we may operate or obtain approvals for Allocetra<SUP>TM</SUP>&nbsp;and any future product candidates.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In some cases, forward-looking
statements are identified by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;hope,&rdquo; &ldquo;targets,&rdquo; &ldquo;potential,&rdquo; &ldquo;goal&rdquo; or &ldquo;continue&rdquo; or the negative of these
terms or other comparable terminology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors
that may cause actual results or performance to differ materially from those suggested in such forward-looking statements. These statements
are current only as of the date of this prospectus and are subject to known and unknown risks, uncertainties, and other factors that may
cause our actual results, levels of activity, performance or achievements to be materially different from those suggested in the forward-looking
statements. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions
of future research or trials would not suggest different conclusions or that historic results referred to in this prospectus or in our
Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which is incorporated by reference in this prospectus, would not
be interpreted differently in light of additional research, clinical and preclinical trials results. Factors which could cause actual
results to differ materially from those indicated by the forward-looking statements include those factors described under the caption
&ldquo;Risk Factors&rdquo; in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which is incorporated by reference
in this prospectus, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus
and in the other documents incorporated by reference in this prospectus. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this prospectus. &nbsp;Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by
law, we do not intend to (and expressly disclaim any such obligation to) update or revise any of the forward-looking statements, whether
as a result of new information, future events or otherwise, after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We may issue and sell up to 8,800,000 ordinary shares from time to
time under this prospectus. The amount of proceeds from this offering will depend upon the aggregate number of ordinary shares sold and
the market price at which they are sold. There can be no assurance that we will be able to sell any ordinary shares under this offering,
nor are the actual proceeds to us from this offering currently determinable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
from this offering for (i)&nbsp;clinical, regulatory, manufacturing and research and development activities; (ii) potential acquisitions
and in-licensing; and (iii) other general corporate purposes. Pending any such uses, we intend to hold the net proceeds in cash and cash
equivalents (which may include investments in highly liquid, short term investment instruments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This expected use of the net
proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and timing of
our actual expenditures may vary significantly depending on numerous factors, including the progress of our development efforts, the status
of and results from clinical trials, as well as any collaborations that we may enter into with third parties, and any unforeseen cash
needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_007"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The
following table presents our capitalization as determined in accordance with United States generally accepted accounting principles as
of December 31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">on an actual basis; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an as adjusted basis, to give effect to the assumed sale of an aggregate of 8,800,000 ordinary shares in this offering at a public offering price of $1.05, the last reported sale price of our ordinary shares on the Nasdaq Capital Market on May 1, 2025, for aggregate gross proceeds of approximately $9,240,000, after deducting estimated commissions and offering expenses payable by us.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">This
table should be read in conjunction with our financial statements and the notes thereto incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As Adjusted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">(U.S. dollars in thousands (except share data))</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Non-Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Other long-term Liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">299</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">299</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shareholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Common stock of NIS 0.40 par value:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Authorized: 45,000,000 shares as of December 31, 2024; Issued and outstanding: 23,650,989 as of December 31, 2024 and 32,450,989 as of December 31, 2024, as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,685</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,653</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">146,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">154,760</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated other comprehensive income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(127,107</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(127,107</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">32,407</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total capitalization</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,888</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">32,706</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The above table is based on
23,650,989 shares outstanding as of December 31, 2024 and excludes, in each case as of December 31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,898,015 options held by our employees, directors and consultants
to purchase ordinary shares under the Company&rsquo;s equity compensation plans at a weighted average exercise price of $5.37 per share,
of which 2,315,048 options were exercisable as of December 31, 2024, at a weighted average exercise price of $5.46 per share;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,234,572 ordinary shares issuable upon vesting of restricted
stock units held by our employees and directors under the 2019 Plan;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,121,494 ordinary shares available for future issuance under
the 2019 Plan as of December 31, 2024; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">7,645,109 ordinary shares issuable upon exercise of warrants
at a weighted average exercise price of $2.007 per share.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_008"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If you invest in the ordinary
shares being offered by this prospectus, you will suffer immediate dilution in the net tangible book value per ordinary share. Our net
tangible book value as of December 31, 2024 was approximately $23.59 million, or approximately $0.997 per share. Net tangible book value
per share represents our total tangible assets less total liabilities, divided by the number of ordinary shares outstanding as of December
31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Dilution in net tangible book value per share represents the difference
between the offering price per share paid by new investors participating in this offering and the net tangible book value per share of
our ordinary shares immediately after this offering. After giving effect to the sale by us of ordinary shares in this offering, assuming
that an aggregate of 8,800,000 ordinary shares are sold at a public offering price of $1.05 per share, the last reported sale price of
our ordinary shares on the Nasdaq Capital Market on May 1, 2025 for aggregate gross proceeds of approximately $9,240,000, and after deducting
the estimated commissions and estimated offering expenses payable by us, our adjusted net tangible book value as of December 31, 2024
would have been approximately $32.40 million, or approximately $0.998 per share. This represents an immediate increase of $0.0013 in net
tangible book value per share to our existing shareholders and an immediate dilution of $0.0514 per share to new investors of ordinary
shares in this offering. The following table illustrates this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Assumed offering price per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of December 31, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in net tangible book value per share attributable to existing shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjusted net tangible book value per share as of December 31, 2024, after giving effect to the offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution per share to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The above discussion and table
are based on 23,650,989 shares outstanding as of December 31, 2024 and excludes, in each case as of December 31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">2,898,015 options held by our employees, directors and consultants to purchase ordinary shares under the Company&rsquo;s equity compensation plans at a weighted average exercise price of $5.37 per share, of which 2,315,048 options were exercisable as of December 31, 2024, at a weighted average exercise price of $5.46 per share;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">1,234,572 ordinary shares issuable upon vesting of restricted stock units held by our employees and directors under the 2019 Plan;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">2,121,494 ordinary shares available for future issuance under the 2019 Plan as of December 31, 2024; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">7,645,109 ordinary shares issuable upon exercise
    of warrants at a weighted average exercise price of $2.007 per share.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">To the extent that any of
these outstanding options or warrants are exercised or we issue additional ordinary shares under our equity incentive plans, there will
be further dilution to new investors. In addition, we may choose to raise additional capital at any time, including during this offering,
due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities
could result in further dilution to new investors participating in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_009"></A>DESCRIPTION OF ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This prospectus describes
the general terms of our ordinary shares, which description is qualified in its entirety by reference to applicable Israeli law and the
terms and provisions contained in our amended and restated articles of association. When we offer to sell ordinary shares, we will describe
the specific terms of such offering in a supplement to this prospectus. Accordingly, for a description of the terms of a particular offering
of our ordinary shares, you must refer to both this prospectus and the applicable prospectus supplement. To the extent the information
contained in the prospectus supplement differs from this summary description, you should rely on the information contained in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Under our amended and restated
articles of association, the total number of shares of all classes of stock that we have authority to issue is 45,000,000 ordinary shares
with a par value of NIS 0.40 per share. As of December 31, 2024, there were 23,650,989 ordinary shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal">Rights, Preferences, Restrictions
of Shares and Shareholders Meetings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>General</I>. Our share capital is NIS 18,000,000 divided into 45,000,000 ordinary shares with a nominal value of NIS 0.40 each. Our ordinary shares may be certificated or uncertificated, subject to the Companies Law.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Voting</I>. The ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of ordinary shares that represent more than 50% of the voting power have the power to elect all the members of our board of directors the (&ldquo;Board of Directors&rdquo;).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Dividend and liquidation rights</I>. Our Board of Directors may declare a dividend to be paid to the holders of our ordinary shares according to their rights and interests in our profits and may fix the record date for eligibility and the time for payment, subject to the Israeli Companies Law 5759 1999 (the &ldquo;Companies Law&rdquo;).&nbsp;&nbsp;No unpaid dividend shall bear interest as against us. Our Board of Directors may determine that a dividend may be paid, wholly or partially, by the distribution of certain of our assets or by a distribution of paid up shares, debentures or debenture stock or any of our securities or of any other companies or in any one or more of such ways in the manner and to the extent permitted by the Companies Law. Our ordinary shares entitle each owner thereof to an equal right to participate in the distribution of the surplus assets of the Company in the event of our liquidation in accordance with the proportionate nominal value of the shares held thereby.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Transfer of shares; record dates</I>. Fully paid up ordinary shares may be freely transferred pursuant to our amended and restated articles of association unless such transfer is restricted or prohibited by another instrument or securities laws. Each shareholder who would be entitled to attend and vote at a general meeting of shareholders is entitled to receive notice of any such meeting. For purposes of determining the shareholders entitled to notice and to vote at such meeting, the Board of Directors will fix a record date.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Voting; annual general and extraordinary meetings</I>. Subject to any rights or restrictions for the time being attached to any class or classes of shares, each shareholder shall have one vote for each share of which he, she or it is the holder. Our amended and restated articles of association do not permit cumulative voting and it is not mandated by Israeli law. Votes may be given either personally or by proxy. A proxy need not be a shareholder. If any shareholder is without legal capacity, he may vote by means of a trustee or a legal custodian, who may vote either personally or by proxy. If two or more persons are jointly entitled to a share then, in voting upon any question, the vote of the person whose name is registered first in the registry of shareholders as the owner of that share shall be accepted, whether in person or by proxy, and he, she or it shall be entitled to vote such share.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Quorum for general meeting</I>. The quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who holds or represent between them at least one-third of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time/date if so specified in the summons or notice of the meeting. At the reconvened meeting, any two or more shareholders present in person or by proxy shall constitute a lawful quorum.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Notice of general meeting</I>. Under the Companies Law, shareholder meetings generally require prior notice of not less than 21 days or, with respect to certain matters, such as election of directors and affiliated party transactions, not less than 35 days. Only shareholders of record as reflected on our share register at the close of business on the date fixed by the Board of Directors as the record date determining the then shareholders who will be entitled to vote, shall be entitled to notice of, and to vote, in person or by proxy, at a general meeting and any postponement or adjournment thereof.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Annual; agenda; calling a general meeting</I>. An annual general meeting of shareholders is required to be held at least once in every calendar year (not later than 15 months after the holding of the last preceding annual general meeting), at such time and place as may be determined by the Board of Directors. At a general meeting, decisions shall be adopted only on matters that were specified on the agenda. The Board of Directors is obligated to call an extraordinary general meeting of the shareholders upon a written request in accordance with the Companies Law. The Companies Law provides that an extraordinary general meeting of shareholder may be called by the Board of Directors or by a request of two directors or 25% of the directors in office, or by shareholders holding at least 5% of the issued share capital of the company and at least 1% of the voting rights, or by shareholders holding at least 5% of the voting rights of the company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Majority vote</I>. Except as otherwise provided in the amended and restated articles of association or the Companies Law, any resolution at a general meeting shall be deemed adopted if approved by the holders of a majority of our voting rights represented at the meeting in person or by proxy and voting thereon. In the case of an equality of votes, the chairman of the meeting shall not be entitled to a casting vote.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><I>Discrimination against shareholders</I>. There are no discriminating provisions in our amended and restated articles of association, against any existing or prospective holders of our ordinary shares as a result of a shareholder holding a substantial number of ordinary shares.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Modification of Class Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If, at any time, the share
capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issuance
of the shares of that class) may be varied with the consent in writing of the holders of all the issued shares of that class, or with
the sanction of a majority vote at a meeting of the shareholders passed at a separate meeting of the holders of the shares of that class.
The provisions of our amended and restated articles of association relating to general meetings shall apply, mutatis mutandis, to every
such separate class meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Unless otherwise provided by the conditions of
issuance, the enlargement of an existing class of shares, or the issuance of additional shares thereof, shall not be deemed to modify
or abrogate the rights attached to the previously issued shares of such class or of any other class. These conditions provide for the
minimum shareholder approvals permitted by the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Restrictions on Shareholders Rights to Own Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association and the laws of the State of Israel do not restrict in any way the ownership or voting or our shares by non-residents of
Israel, except with respect to subjects of countries which are in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Securities Register</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We are registered with the
Israeli Registrar of Companies. Our registration number is 51-471648-9. Our amended and restated articles of association provide that
we may engage in any type of lawful business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal">Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law requires
that certain transactions, actions and arrangements be approved as provided for in a company&rsquo;s articles of association and in certain
circumstances by the Company&rsquo;s Audit Committee or the Company&rsquo;s Compensation Committee, by the Board of Directors itself and
by the shareholders. The vote required by the Audit Committee, Compensation Committee and the Board of Directors for approval of such
matters, in each case, is a majority of the disinterested directors participating in a duly convened meeting. If, however, a majority
of the members participating in such meeting have a personal interest in the approval of such matter, then all directors may participate
in the discussions and the voting on approval thereof and in such case the matter shall be subject to further shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder promptly disclose to the Company any personal interest that he or she may have and all related material information
or documents relating to any existing or proposed transaction by the Company. An interested office holder&rsquo;s disclosure must be made
promptly and in any event no later than the first meeting of the Board of Directors at which the transaction is considered. An office
holder is not obliged to disclose such information if the personal interest of the office holder derives solely from the personal interest
of his or her relative in a transaction that is not considered as an extraordinary transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The term &ldquo;personal interest&rdquo;
is defined under the Companies Law to include the personal interest of a person in an action or in the business of a company, including
the personal interest of such person&rsquo;s relative or the interest of any corporation in which the person is an interested party, but
excluding a personal interest stemming solely from the fact of holding shares in such company. A personal interest furthermore includes
the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with respect to
his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal interest
in the approval of the matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
extraordinary transaction is defined as any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">a transaction other than in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">a transaction that is not on market terms; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">a transaction that may have a material impact on a company&rsquo;s profitability, assets or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If it is determined that an
office holder has a personal interest in a transaction that is not an extraordinary transaction, approval by the board of directors is
required for the transaction, unless the company&rsquo;s articles of association provide for a different method of approval. Approval
first by the company&rsquo;s Audit Committee and subsequently by the board of directors is required for an extraordinary transaction in
which an office holder has a personal interest. Further, so long as an office holder has disclosed his or her personal interest in a transaction,
the board of directors may approve an action by the office holder that would otherwise be deemed a breach of duty of loyalty. However,
a company may not approve a transaction or action that is adverse to the company&rsquo;s interest or that is not performed by the office
holder in good faith. Arrangements regarding the compensation, indemnification or insurance of an office holder require the approval of
the Compensation Committee, board of directors and, in certain circumstances, the shareholders, in that order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to Israeli law, the
disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder
of a public company. In the context of a transaction involving a controlling shareholder or an officer who is a controlling shareholder
of the company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting rights if no other shareholder
holds more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval of the same transaction are
deemed to be a single shareholder and may be deemed a controlling shareholder for the purpose of approving such transaction. Extraordinary
transactions, including private placement transactions, with a controlling shareholder or in which a controlling shareholder has a personal
interest, and engagements with a controlling shareholder or his or her relative, directly or indirectly, including through a corporation
in his or her control, require the approval of the Audit Committee, the Board of Directors and the shareholders of the company, in that
order. In addition, the shareholder approval must fulfill one of the following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">at least a majority of the shares held by shareholders who do not have a personal interest in the transaction
and who are present and voting, in person, by proxy or by voting deed at the meeting, are voted in favor of the transaction (excluding
abstentions); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt">&#9679;</TD><TD STYLE="text-align: justify">the votes of shareholders who have no personal interest in the transaction and who are present and voting,
in person, by proxy or by voting deed at the meeting, and who vote against the transaction may not represent more than two percent (2%)
of the voting rights of the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">To the extent that any such
transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years,
unless the Audit Committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Arrangements regarding the
terms of engagement and compensation of a controlling shareholder who is an office holder, and the terms of employment of a controlling
shareholder who is an employee of the company, require the approval of the Compensation Committee, Board of Directors and, generally,
the shareholders (by the same special majority described above), in that order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to Israeli law, a
director who has a personal interest in an extraordinary transaction which is brought for discussion before our Board of Directors or
our Audit Committee shall neither vote in nor attend discussions concerning the approval of such transaction. If the director did vote
or attend as aforesaid, the approval given to the aforesaid activity or arrangement will be invalid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide that, subject to the Companies Law, our Board of Directors may delegate its authority, in whole or in part, to
such committees of the Board of Directors as it deems appropriate, and it may from time to time revoke such delegation. To the extent
permitted by the Companies Law, our Board of Directors may from time to time confer upon and delegate to a President, Chief Executive
Officer, Chief Operating Officer or other executive officer then holding office, such authorities and duties of the Board of Directors
as it deems fit, and they may delegate such authorities and duties for such period and for such purposes and subject to such conditions
and restrictions which they consider in our best interests, without waiving the authorities of the Board of Directors with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Arrangements regarding compensation
of directors require the approval of our Compensation Committee, our Board of Directors and the shareholders.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal">Acquisitions under Israeli
Law</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Full tender offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share
capital or of the issued and outstanding share capital of a certain class of shares is required by the Companies Law to make a tender
offer to all of the company&rsquo;s shareholders for the purchase of all of the issued and outstanding shares of the company or of all
of the issued and outstanding shares of the same class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If the shareholders who do
not respond to or do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class of the shares, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of
the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer also
will be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition the Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If (a) the shareholders who
did not respond or accept the tender offer&nbsp;hold&nbsp;at&nbsp;least&nbsp;5%&nbsp;of the issued and outstanding share capital of the
company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not
have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or
more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the
company that will increase its holdings to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable
class from shareholders who accepted the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Special tender offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of at least 25% of the voting rights in the company. This rule does not apply if there is already
another holder of at least 25% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Similarly, the Companies Law
provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company
who holds more than 45% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">These requirements do not
apply if the acquisition (i) occurs in the context of a private offering, on the condition that the shareholders meeting approved the
acquisition as a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no
person who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to give the acquirer 45%
of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a shareholder
holding at least 25% of the voting rights in the company and resulted in the acquirer becoming a holder of at least 25% of the voting
rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming
a holder of more than 45% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The special tender offer may
be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the
offeror and (ii) the special tender offer is accepted by a majority of the votes of those offerees who gave notice of their position in
respect of the offer; in counting the votes of offerees, the votes of a holder of control in the offeror, a person who has personal interest
in acceptance of the special tender offer, a holder of at least 25% of the voting rights in the company, or any person acting on their
or on the offeror&rsquo;s behalf, including their relatives or companies under their control, are not taken into account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability of the offer or shall
abstain from expressing any such opinion if it is unable to do so, provided that it gives the reasons for its abstention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An office holder in a target
company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing
or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders
for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds to believe he or she was
acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order
to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If a special tender offer
was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who did not respond to the special
offer or had objected to the special tender offer may accept the offer within four days of the last day set for the acceptance of the
offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is accepted, then the purchaser or any person or entity controlling it and any corporation controlled by them shall refrain
from making a subsequent tender offer for the purchase of shares of the target company and may not execute a merger with the target company
for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or
merger in the initial special tender offer.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Merger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&rsquo;s Board of Directors and, unless certain requirements described under the Companies
Law are met, a majority of each party&rsquo;s shareholders, by a majority of each party&rsquo;s shares that are voted on the proposed
merger at a shareholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Board of Directors of
a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable
concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors,
taking into account the financial condition of the merging companies. If the Board of Directors has determined that such a concern exists,
it may not approve a proposed merger. Following the approval of the Board of Directors of each of the merging companies, the Boards of
Directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">For purposes of&nbsp;the shareholder
vote,&nbsp;unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding shares
or the right to appoint 25% or more of the directors of the other party, vote against the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If the transaction would have
been approved but for the separate approval of each class of shares or the exclusion of the votes of certain shareholders as provided
above, a court may still rule that the company has approved the merger upon the request of holders of at least 25% of the voting rights
of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal of the merging companies&rsquo;
value and the consideration offered to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Under the Companies Law, each
merging company must send a copy of the merger proposal to its secured creditors. Unsecured creditors are entitled to receive notice of
the merger, as provided by the regulations promulgated under the Companies Law. Upon the request of a creditor of either party to the
proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of
the merger, the surviving company will be unable to satisfy the obligations of the target company. The court may also give instructions
in order to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed with the Israeli
Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Potential Issues that Could Delay a Merger</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Certain provisions of Israeli
corporate and tax law may have the effect of delaying, preventing or making more difficult any merger or acquisition of us.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal">Requirement of Disclosure
of Shareholder Ownership</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">There are no provisions of
our amended and restated articles of association governing the ownership threshold above which shareholder ownership must be disclosed.
We are subject, however, to U.S. securities rules that require beneficial owners of more than 5% of our ordinary shares to make certain
filings with the SEC.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal">Changes in Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association do not impose any conditions governing changes in capital that are more stringent than required by the Companies Law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Listing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed
on the Nasdaq Capital Market under the symbol &ldquo;ENLV&rdquo; and on the Tel Aviv Stock Exchange under the symbol &ldquo;ENLV.&rdquo;&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have entered into the Sales Agreement, dated as of December 30,
2022, with the Sales Agents as sales agents, under which we may elect to sell up to 8,800,000 ordinary shares from time to time through
the Sales Agents as our agents. The Sales Agreement provides that if we elect from time to time to sell ordinary shares under this prospectus,
such sales may be made in sales deemed to be &ldquo;at-the-market&rdquo; equity offerings as defined in Rule 415(a)(4) promulgated under
the Securities Act, including sales made directly on the Nasdaq Capital Market or sales made to or through a market maker other than on
an exchange, or otherwise, directly to a Sales Agent as principal, in negotiated transactions at market prices prevailing at the time
of sale or at prices related to such prevailing market prices, or in any other method permitted by law, which may include block trades.
From time to time during the term of the Sales Agreement, we may deliver a sales notice to a Sales Agent specifying the length of the
selling period, the amount of ordinary shares to be sold and the minimum price below which sales may not be made. Once we have so instructed
a Sales Agent, unless such Sales Agent declines to accept the terms of the notice, such Sales Agent has agreed to use its commercially
reasonable efforts consistent with its normal trading and sales practices to sell such ordinary shares up to the amount specified on such
terms. We or the Sales Agents may suspend the offering of our ordinary shares hereunder at any time upon proper notice and subject to
other conditions, at which time any standing sales notice will immediately terminate. Settlement for sales of our ordinary shares will
occur at 10:00 a.m. (New York City time), or at some other time that is agreed upon by us and the applicable Sales Agent in connection
with a particular sales notice, on the first trading day following the date any sales were made. The obligations of a Sales Agent under
the Sales Agreement to sell ordinary shares are subject to a number of conditions, which such Sales Agent may waive in its sole discretion.
Sales of our ordinary shares as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company
or by such other means as we and the Sales Agents may agree upon. There is no arrangement for funds to be received in an escrow, trust
or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we elect from time to time
to sell ordinary shares pursuant to this prospectus, we will pay a Sales Agent a commission equal to 3.0% of the gross sales price per
ordinary share issued by us and sold through such Sales Agent. Because there is no minimum offering amount required as a condition to
this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We
have also agreed to reimburse the Sales Agents for certain specified expenses, including the fees and disbursements of their legal counsel
in an amount not to exceed $50,000. Additionally, pursuant to the terms of the Sales Agreement, we have agreed to reimburse the Sales
Agents for the documented fees and costs of their legal counsel reasonably incurred in connection with the Sales Agents&rsquo; ongoing
diligence, drafting and other filing requirements arising from the transactions contemplated by the Sales Agreement in an amount not to
exceed $5,000 in the aggregate per calendar quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In connection with the potential
future sales of the ordinary shares on our behalf under the Sales Agreement, a Sales Agent will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the compensation of such Sales Agent will be deemed to be underwriting commissions or discounts.
We have agreed to provide indemnification and contribution to the Sales Agents and specified other persons against certain civil liabilities,
including liabilities under the Securities Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We will report at least quarterly
the number of our ordinary shares sold through the Sales Agents, as our sales agents, in this offering and, to the extent applicable,
the number of our ordinary shares issued upon settlement of any terms agreements, and the net proceeds to us in connection with such sales
of our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The offering of our ordinary
shares pursuant to the Sales Agreement will terminate upon the earliest of (1) the sale of all our ordinary shares subject to the Sales
Agreement; or (2) termination of the Sales Agreement at the election of either us or the Sales Agents as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">To the extent required by
Regulation M under the Exchange Act, neither Sales Agent will engage in any market making activities involving our ordinary shares or
ordinary shares while the offering is ongoing under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Each Sales Agent and its affiliates
may in the future provide various investment banking and other financial services for us and our affiliates, for which services they may
in the future receive customary fees. We estimate that the total expenses for the offering, excluding compensation and reimbursements
payable to the Sales Agents under the terms of the Sales Agreement, but including expenses paid prior to the date of this prospectus,
will be approximately $145,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Greenberg Traurig, P.A., Miami,
Florida, has passed upon certain legal matters regarding the securities offered hereby under U.S. Law. The validity of the securities
offered hereby and certain matters of Israeli law will be passed upon for us by FISCHER (FBC &amp; Co.) and Greenberg Traurig P.A. Ellenoff
Grossman &amp; Schole LLP, New York, New York, is counsel for the Sales Agents in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our audited consolidated financial
statements included in our Annual Report on Form 20-F for the year ended December 31, 2024 are incorporated herein by reference in reliance
on the report of Yarel + Partners, an independent registered public accounting firm, given on the authority of such firm as an expert
in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_013"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We file annual reports on
Form 20-F, reports on Form 6-K, and other information with the SEC under the Exchange Act. The SEC maintains an Internet site that contains
reports and other information that we file electronically with the SEC and which are available at the SEC&rsquo;s website at http://<I>www.sec.gov</I>.
In addition, we maintain an Internet website at <I>www.enlivex.com</I>. Information contained on or accessible through our website is
not incorporated into or made a part of this prospectus or the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement on Form F-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does
not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the
registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC&rsquo;s website
listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_014"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it, which means that we can disclose important information to you by referring to those
documents. The information incorporated by reference is an important part of this prospectus, and certain information that we file later
with the SEC will update, modify and supersede this information. We incorporate by reference the following documents we have filed with
the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm">Form
20-F</A> for the year ended December 31, 2024, filed with the SEC on April 30, 2025; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Company&rsquo;s Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000114420414045171/v384900_8a12b.htm">Form
8-A</A> filed with the SEC on July 28, 2014, in which there is described the terms, rights and provisions applicable to the shares of
the Company&rsquo;s ordinary shares, including any amendment or report filed for the purpose of updating such description, including
the description of ordinary shares filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019ex2-1_enlivex.htm">Exhibit
2.1</A> to the Company&rsquo;s  <A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019_enlivextherap.htm">Form
20-F</A> filed April 30, 2020.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All annual reports we file
with the SEC pursuant to the Exchange Act on Form 20-F after the date of this prospectus and prior to termination or expiration of this
registration statement shall be deemed incorporated by reference into this prospectus and to be part hereof from the date of filing of
such documents. We may incorporate by reference any Form 6-K subsequently submitted to the SEC by identifying in such Form 6-K that it
is being incorporated by reference into this prospectus (including any such Form 6-K that we submit to the SEC after the date of the filing
of the registration statement of which this prospectus forms a part and prior to the date of effectiveness of such registration statement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Any statements made in this
prospectus or in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed to be modified or
superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed
document that is also incorporated or deemed to be incorporated by reference in this prospectus modifies or supersedes the statement.
Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We will provide without charge
to each person, including any shareholder, to whom a prospectus is delivered, upon written or oral request of that person, a copy of any
and all of the information incorporated by reference into this prospectus. Please direct requests to us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Attention: Shachar Shlosberger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">14 Einstein Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Ness Ziona</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Israel 7403618</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Tel: +972.2.6708072</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Exhibits to the filings will
not be sent, however, unless those exhibits have specifically been incorporated by reference in such filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to 8,800,000 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>







































































<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-size: 12pt"><B>Cantor</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-size: 12pt"><B>Citizens Capital Markets</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">INFORMATION NOT REQUIRED IN PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Item
8. Indemnification of Directors and Officers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may not exculpate an office holder (as defined in the Companies Law and including executive officers and directors) from liability
for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole
or in part, for damages caused to the company as a result of a breach of the duty of care, provided that a provision authorizing such
exculpation is included in its articles of association. Our amended and restated articles of association include such provision. The Company
may not exculpate a director from liability arising out of a prohibited dividend or distribution to shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
Israeli company may indemnify an office holder in respect of certain liabilities either in advance of an event or following an event provided
that a provision authorizing such indemnification is inserted in its articles of association. Our Articles of Association contain such
a provision. An undertaking provided in advance by an Israeli company to indemnify an office holder with respect to a financial liability
imposed on him or her in favor of another person pursuant to a judgment, settlement or arbitrator&rsquo;s award approved by a court must
be limited to events that, in the opinion of the Board of Directors, can be foreseen based on the company&rsquo;s activities when the
undertaking to indemnify is given, and to an amount or a criteria determined by the Board of Directors as reasonable under the circumstances,
and such undertaking must detail the abovementioned events and amount or criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed as an office holder,
either in advance of an event or following an event, provided a provision authorizing such indemnification is contained in its articles
of association:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Monetary liabilities or obligations imposed on the office holder in favor of another person pursuant to a court judgment, including a compromise judgment or an arbitrator&rsquo;s decision approved by a court;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reasonable litigation expenses, including attorney&rsquo;s fees, incurred by the office holder (i) in consequence of an investigation or proceeding conducted against the office holder by an authority that is authorized to conduct such investigation or proceeding, and which was concluded without the filing of an indictment against the office holder and without imposing on the office holder any financial obligation in lieu of criminal proceedings, or which was concluded without the filing of an indictment against the office holder but with imposing on such office holder a financial obligation in lieu of criminal proceedings in respect of an offense that does not require proof of criminal intent or (ii) in connection with a financial sanction; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reasonable litigation expenses, including
attorney&rsquo;s fees incurred by the office holder or imposed upon him by a court, in a proceeding brought against the office holder
by the Company or on its behalf or by another person, or in a criminal proceeding in which the office holder is acquitted, or in a criminal
proceeding in which the office holder is convicted of an offense that does not require proof of criminal intent.&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our amended and
restated articles of association also contain provisions authorizing indemnification of directors and office holders with respect of the
following liabilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payments which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities Law, 1968 (the &ldquo;Securities Law&rdquo;) and expenses the office holder incurred in connection with a proceeding under Chapters H&rsquo;3, H&rsquo;4 or I&rsquo;1 of the Securities Law, including reasonable litigation expenses, including attorney&rsquo;s fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expenses incurred by the office holder in connection with a proceeding under Chapter G&rsquo;1, of the Economic Competition Law, 1988 (the &ldquo;Competition Law&rdquo;), including reasonable litigation expenses, including attorney&rsquo;s fees; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any other liability, obligation or expense indemnifiable or which may from time to time be indemnifiable by law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
Securities Law and the Competition Law, a company may insure an office holder against the following liabilities incurred for acts performed
as an office holder if and to the extent provided in the company&rsquo;s articles of association:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a breach of the duty of loyalty to the Company, provided that the office holder acted in good faith and had a reasonable basis to believe that such act would not prejudice the interests of the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a breach of the duty of care to the Company or to any other person, to the extent such a breach arises out of the negligent conduct of an office holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">monetary liabilities or obligations imposed on him in favor of another person;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a payment which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities Law and expenses that the office holder incurred in connection with a proceeding under Chapters H&rsquo;3, H&rsquo;4 or I&rsquo;1 of the Securities Law, including reasonable litigation expenses, including attorney&rsquo;s fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expenses incurred by the office holder in connection with a proceeding under Chapter G&rsquo;1, of the Competition Law, including reasonable litigation expenses, including attorney&rsquo;s fees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may not indemnify, exculpate or insure an office holder against any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty in the event the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out only of the negligent conduct of the office holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an act or omission committed with intent to derive illegal personal gain; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a fine, a civil fine, a monetary liability or forfeit levied against the office holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, exculpation,
indemnification and insurance of office holders must be approved by the compensation committee, the board of directors and (under certain
circumstances) by the shareholders, in the event it is required under the Companies Law (subject to certain exceptions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Securities Law provides
that a company cannot obtain insurance against or indemnify a third party (including its officers and employees) for any administrative
procedure conducted or monetary fine imposed by the Israeli Securities Authority. However, the Securities Law does permit insurance coverage
and indemnification for certain liabilities incurred in connection with such an administrative procedure, such as reasonable legal fees,
administrative fines and certain compensation payable to injured parties for damages suffered by them, provided that such insurance and/or
indemnification is permitted under the company&rsquo;s articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate, indemnify and insure our office holders for any liability, including under the Securities Law,
to the extent permitted thereunder, imposed on them as a consequence of an act (including any omission) which was performed by virtue
of being an office holder. Our office holders are currently covered by a directors and officers&rsquo; liability insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate, indemnify and insure each of our directors and officers to the fullest extent permitted by the
Companies Law. We have entered into agreements with each of our directors and officers, exculpating them, to the fullest extent permitted
by the Companies Law, from liability for monetary or other damages due to, or arising or resulting from, a breach of the duty of care
to the Company and undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities
resulting from certain acts performed by such office holders in their capacity as an office holder of the Company, our subsidiaries or
affiliates. The indemnification is limited both in terms of amount and coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">ITEM
9. EXHIBITS</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 90%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000114420419016097/tv516517_ex99-2.htm">Amended and Restated Articles of Association of the Company (filed as Exhibit 99.2 to the Company&rsquo;s Report on Form 6-K, filed with the SEC on March 27, 2019 and incorporated by reference herein)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Unit Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea024050101ex5-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of FISCHER (FBC &amp; Co.)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea024050101ex5-2_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Greenberg Traurig, P.A.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1596812/000121390022084015/ea171003ex10-1_enlivexthera.htm">Sales Agreement, dated December 30, 2022, by and among Enlivex Therapeutics Ltd. and Cantor Fitzgerald &amp; Co. and JMP Securities LLC (filed as Exhibit 10.1 to the Company&rsquo;s Report on Form 6-K, filed with the SEC on December 30, 2022 and incorporated by reference herein)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea024050101ex23-1_enlivex.htm">Consent of Yarel + Partners, independent registered certified public accounting firm</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea024050101ex5-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of FISCHER (FBC &amp; Co.) (contained in legal opinion filed as Exhibit 5.1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea024050101ex5-2_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Greenberg Traurig, P.A. (contained in legal opinion filed as Exhibit 5.2)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#poa_001">Powers of Attorney (included on the signature page to this Registration Statement)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea024050101ex-fee_enlivex.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">To be filed by amendment or as an exhibit to a document incorporated
by reference herein in connection with an offering of the offered securities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">ITEM
10. UNDERTAKINGS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) To
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Provided</U>, <U>however</U>,
that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section
13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained
in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) To
file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at
the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section
10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment,
financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in
the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration
statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section
10(a)(3) of the Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with
or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the Form F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5) That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Each prospectus filed
by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Each prospectus required
to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an
offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the
Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form
of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the
prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date
shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which
that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering
thereof. <U>Provided</U><I>, </I><U>however</U><I>,</I> that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6) That,
for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) The portion of any other
free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant&rsquo;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of
such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned registrant
hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) For purposes of determining
any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or
497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) For the purpose of determining
any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of Nes-Ziona, State of Israel, on May 2, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enlivex Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <FONT>Oren Hershkovitz</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shachar Shlosberger</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shachar Shlosberger</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="poa_001"></A>POWER OF ATTORNEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>KNOW ALL MEN BY THESE PRESENTS,
</B>that each person whose signature appears below constitutes and appoints Shai Novik and Shachar Shlosberger and each of them such person&rsquo;s
true and lawful attorney-in-fact and agent, for such person and in such person&rsquo;s name, place and stead, in any and all capacities,
to sign any and all amendments, including post-effective amendments, to this registration statement or any registration statement relating
to this offering to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorney-in-fact
and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all
intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent
or such person&rsquo;s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shachar Shlosberger </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shachar Shlosberger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shai Novik </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025 &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shai Novik</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Abraham Havron </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraham Havron, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gili Hart </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gili Hart, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Roger Pomerantz </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger Pomerantz, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Andrew Singer </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Singer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Signature of Authorized
U.S. Representative of Registrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Enlivex Therapeutics
Ltd., has signed this Registration Statement on May 2, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Colleen De Vries</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colleen De Vries</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Vice President on behalf of Cogency Global Inc.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 60; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea024050101ex5-1_enlivex.htm
<DESCRIPTION>OPINION OF FISCHER (FBC & CO.)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt; width: 20%">Tel. 972-3-69441111</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt">Fax. 972-3-6091116</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt">fbc@fbclawyers.com</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">14 Einstein Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ness Ziona, Israel 7403618</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Re: <U>Enlivex Therapeutics Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as Israeli counsel
to Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the &ldquo;<U>Company</U>&rdquo;), in connection
with the registration statement on Form F-3 to be filed by the Company with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;)
pursuant to the U.S. Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) (the &ldquo;<U>Registration Statement</U>&rdquo;),
which contains two prospectuses (i) a sales agreement prospectus covering the offer and sale by the Company, from time to time, of up
to 8,800,000 ordinary shares (the &ldquo;<U>ATM Shares</U>&rdquo;), par value NIS 0.40 per share (&ldquo;<U>Ordinary Shares</U>&rdquo;)
that may be sold under the Sales Agreement, dated December 30, 2022, by and among the Company, Cantor Fitzgerald &amp; Co. and Citizens
JMP Securities, LLC (the &ldquo;<U>Sales Agreement</U>&rdquo;), and (ii) a base prospectus covering the offer and sale by the Company,
from time to time, of up to $300,000,000, in the aggregate, of any one or more of the following types of securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Ordinary Shares (the &ldquo;<U>Primary Shares</U>&rdquo; and together with the ATM Shares, the &ldquo;<U>Registered
Shares</U>&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">warrants to purchase Ordinary Shares (&ldquo;<U>Warrants</U>&rdquo;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">units to purchase any combination of Ordinary Shares and Warrants (&ldquo;<U>Units</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Primary Shares registered
under the Registration Statement include (i) 3,571,429 Ordinary Shares issuable upon the exercise of certain Series A warrants issued
on May 29, 2024, (ii) 3,571,429 Ordinary Shares issuable upon the exercise of certain Series B warrants issued on May 29, 2024, (iii)
125,000 Ordinary Shares issuable upon the exercise of certain Series A placement agent warrants issued on May 29, 2024, and (iv) 125,000
Ordinary Shares issuable upon the exercise of certain Series B placement agent warrants issued on May 29, 2024 (such warrants, collectively,
the &ldquo;<U>2024 Warrants</U>&rdquo; and the underlying Ordinary Shares, the &ldquo;<U>2024 Warrant Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ATM Shares, Primary Shares,
Warrants, and Units are collectively referred to herein as the &ldquo;<U>Securities</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is furnished
to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, in connection
with the filing of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection herewith, we have
examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the form of the Registration
Statement, to which this opinion letter is attached as an exhibit; (ii) a copy of the articles of association of the Company, as amended
and currently in effect (the &ldquo;<U>Articles</U>&rdquo;); (iii) resolutions of the board of directors of the Company (the &ldquo;<U>Board</U>&rdquo;)
and committees of the Board; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates
or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary
as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant
and necessary as a basis for the opinions hereafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In such examination, we have
assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us
as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies and the authenticity
of the originals of such latter documents. We have assumed the same to have been properly given and to be accurate. We have also assumed
the truth of all facts communicated to us by the Company and that all consents and minutes of meetings of committees of the Board, the
Board and the shareholders of the Company that have been provided to us are true and accurate and have been properly prepared in accordance
with the Articles and all applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assumed, in addition,
that at the time of the execution and delivery of any definitive purchase, underwriting or similar agreement between the Company and any
third party pursuant to which any of the Securities may be issued (a &ldquo;<U>Securities Agreement</U>&rdquo;), the Securities Agreement
will be the valid and legally binding obligation of such third party, enforceable against such third party in accordance with its terms.
We have further assumed that at the time of the issuance and sale of any of the Securities, the terms of the Securities, and their issuance
and sale, will have been established so as not to violate any applicable law or result in a default under or breach of any agreement or
instrument binding upon the Company and so as to comply with any requirement or restriction imposed by any court or governmental body
having jurisdiction over the Company. In addition, for purposes of our opinion, we have assumed that, at the time of issuance and sale
of the Registered Shares, a sufficient number of Ordinary Shares shall be authorized and available for issuance under the Articles as
then in effect and that the consideration for the issuance and sale of the Registered Shares shall be in an amount that is not less than
the nominal (par) value of the Ordinary Shares. We have further assumed the effectiveness of the Registration Statement (including any
post-effective amendments) under the Securities Act, and that such effectiveness shall not have been terminated or rescinded, at the time
of the offer and sale of any of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject to the
foregoing, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Assuming (a) that prior to the issuance of any of the ATM Shares under the Sales Agreement, the price, number
of ATM Shares and certain other terms of issuance with respect to any specific placement notice delivered under the Sales Agreement will
be authorized and approved by the Board or a pricing committee of the Board in compliance with applicable Israeli law and all corporate
proceedings necessary for the authorization, issuance and delivery of the ATM Shares shall have been taken, and (b) receipt by the Company
of the consideration for the ATM Shares in such amount as has been authorized and approved by the Board, or in amount as may be authorized
and approved by the Board or a pricing committee of the Board from time to time in accordance with Israeli law, upon issuance pursuant
to the terms of the Sales Agreement and in accordance with resolutions of the Board related to the offering of the ATM Shares, the ATM
Shares will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assuming (a) the taking of all necessary corporate action to authorize and
approve the issuance of any Primary Shares, the terms of the offering thereof and related matters (for purposes of this paragraph, the
&ldquo;<U>Authorizing Resolutions</U>&rdquo;), (b) the delivery and filing of an appropriate prospectus supplement with respect to the
offering of the Primary Shares in compliance with the Securities Act and the applicable rules and regulations thereunder, (c) approval
by the Board of, and entry by the Company into, and performance by the Company under, any applicable Securities Agreement, in the form
filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Report of Foreign Private Issuer on Form
6-K, pursuant to which the Primary Shares may be issued and sold, and (d) receipt by the Company of the consideration for the Primary
Shares as provided for in the Authorizing Resolutions and in accordance with the provisions of any such Securities Agreement and the applicable
convertible Securities, if any, pursuant to which the Primary Shares may be issued, the Primary Shares (excluding the 2024 Warrant Shares,
which are addressed in the following opinion) will be validly issued, fully paid and non-assessable.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">The 2024 Warrant Shares have been duly authorized for issuance and sale pursuant to the respective 2024 Warrant
by all necessary corporate action on the part of the Company and, when issued, delivered and paid for in accordance with the terms and
conditions of the respective 2024 Warrant, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">You have informed us that you
intend to issue the Securities from time to time on a delayed or continuous basis, and this opinion is limited to the laws, including
the rules and regulations, as in effect on the date hereof. We understand that prior to issuing any Securities you will afford us an opportunity
to review the corporate approval documents and operative documents pursuant to which such Securities are to be issued (including an appropriate
prospectus supplement), and we will file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary
or appropriate by reason of the terms of such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 28.35pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of our firm are admitted
to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion is limited
to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption &ldquo;Legal Matters&rdquo;
and &ldquo;Enforceability of Civil Liabilities&rdquo; in the prospectus constituting part of the Registration Statement. In giving this
consent, we do not thereby admit that we are an &ldquo;expert&rdquo; within the meaning of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is rendered
as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought
to our attention after the date hereof that may alter, affect or modify the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">/s/ FISCHER (FBC &amp; Co.)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FISCHER (FBC &amp; Co.)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.15in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>ea024050101ex5-2_enlivex.htm
<DESCRIPTION>OPINION OF GREENBERG TRAURIG, P.A.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><IMG SRC="ex5-2_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: center; text-indent: 0.5in">May 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14 Einstein Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nes Ziona, Israel 7403618</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enlivex Therapeutics Ltd. Shelf Registration
Statement on Form F-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as legal counsel
for Enlivex Therapeutics Ltd., a company organized under the Laws of the State of Israel (the &ldquo;<U>Company</U>&rdquo;), in connection
with the preparation of a Shelf Registration Statement on Form F-3, including the base prospectus (the &ldquo;<U>Base Prospectus</U>&rdquo;)
constituting a part thereof (the &ldquo;<U>Registration Statement</U>&rdquo;), being filed by the Company with the Securities and Exchange
Commission (the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;),
relating to the Company&rsquo;s offering of up to an aggregate of up to $300,000,000 of any combination of: (i)&nbsp;ordinary shares,
NIS 0.40 per share, of the Company (&ldquo;<U>Ordinary Shares</U>&rdquo;), inclusive of an aggregate of up to 7,392,858 Ordinary Shares
that may be issued pursuant to outstanding warrants offered and sold under the Company&rsquo;s registration statement on Form F-3 declared
effective on May 5, 2022 (Registration No. 333-264561), consisting of 3,571,429 Ordinary Shares issuable upon the exercise of certain
Series A warrants issued on May 29, 2024, (ii) 3,571,429 Ordinary Shares issuable upon the exercise of certain Series B warrants issued
on May 29, 2024, (iii) 125,000 Ordinary Shares issuable upon the exercise of certain Series A placement agent warrants issued on May 29,
2024, and (iv) 125,000 Ordinary Shares issuable upon the exercise of certain Series B placement agent warrants issued on May 29, 2024
(such warrants, collectively, the &ldquo;<U>2024 Warrants</U>&rdquo;); (ii)&nbsp;warrants to purchase Ordinary Shares (&ldquo;<U>Warrants</U>&rdquo;);
and (iii) purchase units consisting of Ordinary Shares and Warrants (&ldquo;<U>Units</U>&rdquo;); and (iv) the Ordinary Shares that may
be issued upon the exercise of the Warrants or in connection with the Units, as applicable. The Ordinary Shares, Warrants and Units that
may be offered and sold by the Company under the Base Prospectus are referred to herein collectively as the &ldquo;<U>Securities</U>.&rdquo;
The Securities may be offered, issued and sold or delivered from time to time as set forth in the Registration Statement, any amendment
thereto, the Base Prospectus contained therein and supplements to the Base Prospectus (the &ldquo;<U>Prospectus Supplements</U>&rdquo;)
and pursuant to Rule 415 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants will be issued
under one or more Warrant Agreements (each, a &ldquo;<U>Warrant Agreement</U>&rdquo;), each to be between the Company and a counterparty
or counterparties identified therein (each, a &ldquo;<U>Counterparty</U>&rdquo;). The Units will be issued under a unit agreement (each,
a &ldquo;<U>Unit Agreement</U>&rdquo;), each to be between the Company and a Counterparty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with our representation
of the Company, and as a basis for the opinions hereinafter set forth, we have examined originals, or copies certified or otherwise identified
to our satisfaction, of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">the Registration Statement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">an English translation of the Company&rsquo;s Articles of Association, as amended to the date hereof (the
&ldquo;<U>Charter</U>&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">the forms of 2024 Warrants filed as exhibits to a report on Form 6-K filed by the Company with the Commission
on May 29, 2024;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">the engagement agreement (the &ldquo;<U>Engagement Agreement</U>&rdquo;) between the Company and H.C.
Wainwright &amp; Co., LLC, pursuant to which the Company issued Series A placement agent warrants and Series B placement agent warrants
on May 29, 2024 as described above (such warrants, the &ldquo;<U>Placement Agent Warrants</U>&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">the securities purchase agreement, dated as of May 27, 2024 (the &ldquo;<U>Securities Purchase Agreement</U>,&rdquo;
and together with the Engagement Agreement and the 2024 Warrants, the <U>&ldquo;2024 Warrant Documents</U>&rdquo;), by and between the
Company and the investor named therein, pursuant to which the Company issued the Series A warrants and the Series B warrants on May 29,
2024 as described above (such warrants, the &ldquo;<U>Investor Warrants</U>&rdquo;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">such other documents and records and other certificates and instruments and matters of law as we have
deemed necessary or appropriate to express the opinions set forth below, in each case subject to the assumptions, limitations and qualifications
stated herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering the opinions
set forth below, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents
submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed
copies and the authenticity of the originals of such latter documents. We have also assumed that (i) at the time of execution, countersignature,
issuance and delivery of any Warrants, each Warrant Agreement will be the valid and legally binding obligation of each Counterparty thereto,
(ii) at the time of execution, countersignature, and issuance and delivery of any Units, each Unit Agreement will be the valid and legally
binding obligation of each Counterparty thereto, (iii) the obligations of each party set forth in the 2024 Warrant Documents are valid
and binding obligations of such party and are enforceable against such party in accordance with all stated terms (other than the Company&rsquo;s
obligations under the 2024 Warrants, to the extent set forth in our opinion below), (iv) each individual that executed any of the 2024
Warrant Documents, whether on behalf of such individual or another person, was legally competent to do so; (v) the due authorization,
adoption, approval, execution and delivery by all parties thereto of the 2024 Warrant Documents; (vi) each of the parties that executed
any of the 2024 Warrant Documents had duly and validly executed and delivered each of such documents to which such party is a signatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As to matters of fact material
to this opinion, we have relied to the extent we deemed reasonably appropriate upon representations or certificates of officers or directors
of the Company, without independently verifying the accuracy of such documents, records and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the issuance
of Warrants, we have assumed further that (i) at the time of execution, countersignature, issuance and delivery of any Warrant Agreement,
such Warrant Agreement will have been duly authorized, executed and delivered by the Company, and (ii) the execution, delivery and performance
by the Company of such Warrant Agreement will not violate the laws of any jurisdiction (provided that as to the federal laws of the United
States we make no such assumption).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the issuance
of the 2024 Warrants, we have assumed further that (i) at the time of execution, countersignature, issuance and delivery of the 2024 Warrants,
the 2024 Warrants had been duly authorized, executed and delivered by the Company, and (ii) the execution, delivery and performance by
the Company of the 2024 Warrants did not violate the laws of any jurisdiction (provided that as to the federal laws of the United States
and the laws of the State of New York we make no such assumption).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the issuance
of Units, we have assumed further that (i) at the time of execution, countersignature, issuance and delivery of any Unit Agreement, such
Unit Agreement will have been duly authorized, executed and delivered by the Company, and (ii) the execution, delivery and performance
by the Company of such Unit Agreement will not violate the laws of any jurisdiction (provided that as to the federal laws of the United
States we make no such assumption).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have further assumed that:
(i)&nbsp;the Registration Statement and any amendments thereto will be effective under the Securities Act, that no stop orders will have
been issued by the Commission with respect to the Registration Statement and that the Registration Statement will comply with all applicable
laws at the time the Securities are offered or issued as contemplated by the Registration Statement; (ii)&nbsp;an appropriate Prospectus
Supplement, free writing prospectus or term sheet relating to the Securities offered thereby will have been prepared and filed with the
Commission in compliance with the Securities Act and will comply with all applicable laws at the time the Securities are offered or issued
as contemplated by the Registration Statement; (iii)&nbsp;all Securities will be issued and sold in compliance with the applicable provisions
of the Securities Act and the securities or blue sky laws of various states and in the manner stated in the Registration Statement and
the applicable Prospectus Supplement; (iv)&nbsp;any purchase, underwriting or similar agreement relating to Securities being offered will
have been duly authorized, executed and delivered by the Company and the other parties thereto; and (v)&nbsp;in connection with the issuance
of any Securities, an adequate number of authorized and unissued Ordinary Shares will be available for issuance under the Charter, as
then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject to
the foregoing, and subject to the assumptions, limitations and qualifications stated herein, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">With respect to the Warrants, assuming (i)&nbsp;the taking of all necessary corporate action by the Company&rsquo;s
board of directors (the &ldquo;<U>Board</U>&rdquo;) to approve the execution and delivery of each Warrant Agreement and (ii) the due execution,
countersignature, issuance and delivery of such Warrant Agreement upon payment of the consideration therefor provided for in the applicable
definitive purchase, underwriting or similar agreement, or the Base Prospectus or a Prospectus Supplement approved by the Board and otherwise
in accordance with the provisions of the applicable Warrant Agreement and such agreement, such Warrants will constitute valid and legally
binding obligations of the Company enforceable against the Company in accordance with their terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">With respect to the 2024 Warrants, assuming (i)&nbsp;the taking of all necessary corporate action by the
Company&rsquo;s board of directors to approve the execution and delivery of the 2024 Warrants, (ii) the due execution, countersignature,
issuance and delivery of the Placement Agent Warrants pursuant to the terms of the Engagement Agreement and (iii) the due execution, countersignature,
issuance and delivery of the Investor Warrants pursuant to the terms of the Securities Purchase Agreement, the 2024 Warrants constitute
valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">With respect to the Units, assuming (i)&nbsp;the taking of all necessary corporate action by the Board
to approve (x) the execution and delivery of the applicable Unit Agreement and (y)&nbsp;any Securities to be issued separately or as part
of any such Units and (ii) the due execution, countersignature, issuance and delivery of such Unit Agreement upon payment of the consideration
therefor provided for in the applicable definitive purchase, underwriting or similar agreement, or the Base Prospectus or a Prospectus
Supplement approved by the Board and otherwise in accordance with the provisions of the applicable Unit Agreement and such agreement,
such Units will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their
respective terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinions set forth above
are subject to (i) the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws now or hereafter
in effect relating to or affecting creditors&rsquo; rights generally, (ii) the effects of general equitable principles, whether enforcement
is considered in a proceeding in equity or law, (iii) an implied covenant of good faith and fair dealing, (iv) the discretion of the court
before which any proceeding for enforcement may be brought and (v)&nbsp;the unenforceability under certain circumstances under law or
court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification
or contribution is contrary to the public policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enlivex Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is limited
to the matters stated herein, and no opinions may be implied or inferred beyond the matters expressly stated herein. We assume no obligation
to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the
opinion expressed herein after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not express any opinion
herein concerning any law other than the laws of the State of New York and the federal securities laws of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion as an exhibit to the Registration Statement and to the use of the name of our firm therein. In giving this consent, we
do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Greenberg Traurig, LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GREENBERG TRAURIG, LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea024050101ex23-1_enlivex.htm
<DESCRIPTION>CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="ex23-1_001.jpg" ALT=""></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="ex23-1_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT ACCOUNTANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
the Registration Statement on Form F-3 of Enlivex Therapeutics Ltd.&nbsp;of our report dated March 31, 2025, with respect to the consolidated
financial statements and the effectiveness of internal control over financial reporting of Enlivex Therapeutics Ltd., filed with the Securities
and Exchange Commission on March 31, 2025. We also consent to the reference to our firm under the wording &ldquo;Experts&rdquo; in such
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Yarel + Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yarel + Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel- Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex23-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ea024050101ex-fee_enlivex.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Calculation of
Filing Fee Tables</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form F-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Enlivex Therapeutics, Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Table 1: Newly Registered and Carry Forward
Securities</U></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Security<BR>

    Type</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Security<BR>

Class <BR>
Title</B></FONT></P></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee<BR>

    Calculation<BR>
 or Carry<BR>
 Forward<BR>
 Rule</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount<BR>

    Registered</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Proposed<BR>

    Maximum<BR>
 Offering<BR>
 Price Per<BR>
 Unit</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Maximum<BR>

    Aggregate<BR>
 Offering Price</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee
    Rate</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount
    of<BR>
 Registration<BR>
 Fee</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry<BR>

    Forward<BR>
 Form&nbsp;Type</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry<BR>

    Forward<BR>
 File<BR>
 Number</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry<BR>

    Forward<BR>
 Initial<BR>
 Effective<BR>
 Date</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Filing
    Fee<BR>
 Previously<BR>
 Paid in<BR>
 Connection<BR>
 with&nbsp;Unsold<BR>
 Securities&nbsp;to<BR>
 be Carried<BR>
 Forward</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fees
    to Be Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 17%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ordinary&nbsp;shares,
    par value NIS 0.40 per share(1)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Units</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unallocated
    (Universal) Shelf</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unallocated
    (Universal) Shelf</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">457(o)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,814,999.17</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.00015310</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,196.48</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="41" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ordinary
    shares, par value NIS 0.40 per share</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ordinary
    shares, par value NIS 0.40 per share(1)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Units</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unallocated
    (Universal) Shelf</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Unallocated
    (Universal) Shelf</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Rule
    415(a)(6)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">283,649,000.83</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.0000927</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">F-3</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">333-264561</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">May&nbsp;5,&nbsp;2022</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">26,294.26</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ordinary
    shares, par value NIS 0.40 per share(1)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Rule
    415(a)(6)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,800,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.97</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,536,000.00</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.0000927</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">F-3</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">333-264561</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">May
    5, 2022</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">791.29</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7)</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="9" STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Offering Amounts</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">300,000,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(5)(7)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,196.48</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="9" STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Fees Previously Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="9" STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Fee Offsets</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"></TD><TD STYLE="padding-bottom: 4pt; font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="9" STYLE="padding-bottom: 4pt; font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    Fee Due</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,196.48</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">In accordance with Rule 416 under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), the registrant&rsquo;s ordinary shares being registered hereunder shall be deemed to cover
any additional ordinary shares to be offered or issued from stock splits, stock dividends, recapitalizations, or similar transactions
with respect to the ordinary shares being registered.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The proposed maximum aggregate offering price per class of security
will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered
hereunder and is not specified as to each class of security pursuant to instructions to Form F-3 under the Securities Act.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">There are being registered hereunder such indeterminate number
of the securities of each identified class being registered as may be sold by the registrant from time to time at indeterminate prices.
Also includes such indeterminate number of securities of the registrant as may be issued upon exercise, conversion or exchange of these
securities. Separate consideration may or may not be received for securities that are issuable upon exercise, conversion or exchange
of other securities.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">The proposed maximum aggregate price per unit of each class
of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities
registered hereunder and is not specified as to each class of securities pursuant to the General Instruction II.C. of Form F-3 under
the Securities Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">The $300,000,000 of securities registered pursuant to the base
prospectus contained in this registration statement includes $283,649,000.83 of unsold securities (the &ldquo;Unsold Securities&rdquo;)
registered pursuant to the Registration Statement on Form F-3 (No. 333-264561), filed on April 29, 2022 (the &ldquo;Prior Registration
Statement&rdquo;). Pursuant to Rule 415(a)(6) under the Securities Act, the $26,294.26 of filing fees previously paid in connection with
the Unsold Securities is hereby carried forward to be applied to the Unsold Securities registered hereunder and will continue to be applied
to the Unsold Securities registered hereunder.&nbsp;To the extent that, after the filing date hereof and prior to the effectiveness of
this registration statement, the registrant sells any Unsold Securities pursuant to the Prior Registration Statement, the Registrant
will identify in a pre-effective amendment to this registration statement the updated number of Unsold Securities from the Prior Registration
Statement to be included in this registration statement pursuant to Rule 415(a)(6). Pursuant to Rule 415(a)(6), the offering of Unsold
Securities registered under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration
statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration
fee pursuant to Rule 457(c) under the Securities Act, on the basis of the average of the high and low prices for an ordinary share on
April 25, 2025, as reported on the Nasdaq Capital Market.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: justify">The registrant previously registered the offer and sale of ordinary
shares having an aggregate offering price of up to $100,000,000 by means of a prospectus supplement filed pursuant to Rule 424(b)(5)
under the Securities Act on December 30, 2022 (the &ldquo;2022 ATM Prospectus Supplement&rdquo;), pursuant to the Prior Registration
Statement. The registration of ordinary shares having a maximum aggregate offering price of $100,000,000 to be issued and sold as part
of an &ldquo;at-the-market&rdquo; offering (the &ldquo;2022 ATM Program&rdquo;) covered by the 2022 ATM Prospectus Supplement represented
$9,270 of aggregate filing fee of $27,810 paid by the registrant to register up to $300,000,000 of securities under the Prior Registration
Statement. Of those ordinary shares, ordinary shares having an aggregate offering price of $2,816,510 have been sold and ordinary shares
with a maximum aggregate offering price of $97,183,490 remain unsold. Pursuant to Rule 415(a)(6) under the Securities Act, the $300,000,000
of securities registered pursuant to this registration statement include the ordinary shares to be issued and sold as part of an &ldquo;at-the-market&rdquo;
offering covered by the 2022 ATM Prospectus Supplement having a maximum aggregate offering price of $8,536,000.00 (the &ldquo;ATM Carry
Forward Securities&rdquo;), and the registration fees totaling $791.29 that were previously paid on April 7, 2022 with respect to the
ATM Carry Forward Securities will continue to be applied to the ATM Carry Forward Securities. Pursuant to Rule 415(a)(6), the offering
of the ATM Carry Forward Securities under the Prior Registration Statement will be deemed terminated as of the effective date of this
registration statement, and the remaining ordinary shares with a maximum aggregate offering price of $88,647,490 unsold under the 2022
ATM Prospectus Supplement are included in the Unsold Securities referenced above.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B 4<# 2(  A$! Q$!_\0
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M_(/S)S7J^C:>NE:+9V*C_41*AY[XY_7-:U(NC0Y7NW^",:<U7Q/.MHQ7WO\
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MHI1BK)!1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  GP# 2(  A$! Q$!_\0
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M,O\ YA*/^(B'_@M+_P!'_?%K_P $?PR_^82OQ=HH _:+_B(A_P""TO\ T?\
M?%K_ ,$?PR_^82C_ (B(?^"TO_1_WQ:_\$?PR_\ F$K\7:* /VB_XB(?^"TO
M_1_WQ:_\$?PR_P#F$H_XB(?^"TO_ $?]\6O_  1_#+_YA*_%VB@#]HO^(B'_
M (+2_P#1_P!\6O\ P1_#+_YA*/\ B(A_X+2_]'_?%K_P1_#+_P"82OQ=HH _
M:+_B(A_X+2_]'_?%K_P1_#+_ .82C_B(A_X+2_\ 1_WQ:_\ !'\,O_F$K\7:
M* /VB_XB(?\ @M+_ -'_ 'Q:_P#!'\,O_F$H_P"(B'_@M+_T?]\6O_!'\,O_
M )A*_%VB@#]HO^(B'_@M+_T?]\6O_!'\,O\ YA*/^(B'_@M+_P!'_?%K_P $
M?PR_^82OQ=HH _:+_B(A_P""TO\ T?\ ?%K_ ,$?PR_^82C_ (B(?^"TO_1_
MWQ:_\$?PR_\ F$K\7:* /VB_XB(?^"TO_1_WQ:_\$?PR_P#F$H_XB(?^"TO_
M $?]\6O_  1_#+_YA*_%VB@#]HO^(B'_ (+2_P#1_P!\6O\ P1_#+_YA*/\
MB(A_X+2_]'_?%K_P1_#+_P"82OQ=HH _:+_B(A_X+2_]'_?%K_P1_#+_ .82
MC_B(A_X+2_\ 1_WQ:_\ !'\,O_F$K\7:* /VB_XB(?\ @M+_ -'_ 'Q:_P#!
M'\,O_F$H_P"(B'_@M+_T?]\6O_!'\,O_ )A*_%VB@#]HO^(B'_@M+_T?]\6O
M_!'\,O\ YA*/^(B'_@M+_P!'_?%K_P $?PR_^82OQ=HH _:+_B(A_P""TO\
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M'_B*L5C:"\5^/'3I87#585?]<^);*=6,Y32?]M6]UI*VMDTFDK'T<G_!1O\
M;R^R0ZC+\>_B*FG7+-#!>KHVA&Q>X62"':U_)X<A@0---)&J;6=OLMPP)521
M8A_X**?M[W*036WQS^)EQ!<.R0.F@6!,[1Q)<-%;&/P5+%<236\L<]NZRK$Z
M)(-Q9HQ7C=WXMTL^'-5U,^,;+4_#FI?"+PCX/TOP09)GU1O'NCZ7X3L]6NX]
M+N;81VC76NZ?J^H7.LIB4?:[F",HM\#'#)\5I+>U\2:78^.M9MM.'P9^&GA?
M2([*_P!2M[>U\4Z1%\.]1UFSLXH[D8N+B?1]3BN[Z$K,8(9K594$\N[#^P^'
MXNRX3R.?][^QLN?RTP/]?B=JXWXVA!2K>,GB'[1T(3=*GQEQ(XIRBVFG_;-[
M]?BT=K]CUJ7_ (*2_MTPX27]H;QY!*A9)$GTSP[$Q=<*YDBET"*>PD617V6M
MS$\DT3K,DJK&PDA_X>5_MS?]'%^,_P#P#\,__**OE;XCZW9>)/$=GKEM<O?3
M7OA#P*NH7K@+-<:K:>#]%LM6^VD "6X%];R2"1@)2\URTS2EU\O@Z]'"\,\,
MUZ2J3X8R&G)RDN5Y/ENBBTD]<%U3N?'8SQ6\3:.(G3PWBAXA5J,;6J3XQXE4
MG)\W,K+.5I%JR^[9*WV_<?\ !23]N*:"?S/VB/&#^5#)+'OL/"L@638T8<)+
MX?="RK(VTE3@G(Y K]P_^"/G[1'QK^/]K\=Y_C!\0]9\<2^%M4\ P:"=2ATJ
MV&G0ZC:^(H[Z.)=,T^Q4K<M86\\N\,3,&8$*VP?RNMCR+H'@&VE_I_G]:_H\
M_P""#>W^SOVER#S_ &U\->/;RO%_ZU^;^,/#F09?X=<0YE@<ERS!8_#8_**-
M#%83!4,/5HTJ\).K"G[&%.FE4:3F_9.3:3<]$?TC]$'CSC?/_'K@G+L]XPXH
MSG 8^OGE/&X3-<_S;,*&*A@^&<9BL+"M#&8_$<T:&(C&M2BI049K[4;P?]#L
M8)?>68Y3&TD;1R#D#&<_CW-3U#%V_P!T?TJ:OXP?Q2VT?1)=%V2^_5OJV?[9
MQ;E"FV[MTX-O35\JUT2_(*BFA6>,Q,TB*S(2T3M&_P CJ^%D0ATW%=I9"KA2
M=C*V&$M%(9\6?#S_ ()Z_LE?"G]H;QY^UAX!^&VL:!^T1\4K*TTSXE?%-?BC
M\6M1UWQWI-BNDBVT?Q/::MXYO]#U/1T;0M(E_LF72AI_GZ?:RBV#PQE?H_XF
M_#/PG\6/!'B/X<^-[?4[_P '>,]*U+P]XFTG3O$_B3PK)J>B:MIT^G:AI@U3
MPIJ>CZY#:W5C++:W%GIVIV"75O-.+AI S!_1*8^<#'4,N#QE=Q"EAD$9"LV,
M@CL010!\"^#O^"9G[#W@/]G74?V0_#'P&TO3_P!F35];TWQ'<_!F_P#%OC[6
M_!=OKNE>+(?'.G:YX:L]?\9ZOJ/A+58/',6G>*3J'AJ[T6_?6K.VNY;AI R3
M>_O\"/AEJ</A;3/$UMK'C31_ &H:=K'A'1O&GBWQ-XGTKP]KFF6T;Z/J\NF>
M(-0N/MNMZ""MWX5U?Q+=Z[KOA^\<:EHEW87=JEU!\1?MP_M.^./V?_VI?V2?
M \/Q/O/A[\%/BO\ #3]KSQG\5)=%^'?A_P ;>([&;X!>$?AKXK\-:EX92_\
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MQ^SKK^I:G<0Z)"=TEQ'H6NW+*8[ @@'\4?\ Q! _ /\ Z/X^,/\ X9/PA_\
M-A1_Q! _ /\ Z/X^,/\ X9/PA_\ -A7]DFF?&Z3Q%X[O?"/A/X=>-O$VA>'_
M !*?"'C'XC6%SX0M/!OAWQ MG#-<V44>L^,=+\5^('T;4)1HOB%?#_A?4%T?
M5([ZUN)?/TNYAD+OX]:!IO[0&A?L]:KH^L6'B+Q+\-1\1-#\0,]E-X<U"6._
MUNSO/!\3?VC#K*>([6S\/ZIKZ%]&&FW.C6ER3>6]Y"MO, ?QM_\ $$#\ _\
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M,\'DWXF6;3I+Z%9O) /XO?\ B"!^ ?\ T?Q\8?\ PR?A#_YL*/\ B"!^ ?\
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M,%^N7L:^AY]'Z%Y+PIR^.EF_[=XPV6EM<W=DKVT2M>VB=C\:O^'$G@7<S?\
M"_O''S,[E1X%T$+N<@\ :]QM"A4&<!>#D\TO_#B7P)_T7SQO_P"$+H7_ ,OZ
M_:;1_C%X2UKXHZS\)+'1_$\WB+0O#;>)+W5Y/#DMCX6GA@U+2]+N[.PU:_>
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MA"KOFPC1LA,KLZF.43$&5RTKK(RHLB2.Z,B* H()+$LXT=I-S,77;(&2#$G
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MX/TV6+1-8U&_O;?1KS1M:_3HVD3 K)F1,(%1UB(14;<4#>6)&60!4E$CN'1
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M::%BT@5!GRUW C#_ %@+:(,S*H1FCCAW(%4K'"6:%%*J"%A:21HQG ,CY!!
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M=+TVZN+34M/U71]7BN!?73VLUB;>.>*UA,\]K$&@NFGCN6DEGNI8X;N'YO\
MA7^S_P",[7XQ_#OQ ^B?%3P3\-_@R?&4GA?PW\0?C'HWCK1Y[Z_\)7G@30=*
M\%>&/#=_XEM]*\+Z3H6M7T^EWOC77&\3Z1'96NEV>F&VNM0EC_1)+=$+%7G.
MXY(>YN)!G@#;YDC%  #\J%4.265B 0YH(W&)%\S*-&2V,M&X(9&P &4@X((Y
MZGDDD ^,['PU\8OAS\,?B]\1_#7@+0?B%^T7\1_%>I^,H?"=UKVG:/IHADU
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GN+E@E&/91BEKK_*R54"G(9CQC!(([<].O%/HHJ=QMM[_ *?HD?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H /<# 2(  A$! Q$!_\0
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M8=KP3E1DC>.>G8YHI5'.^E_Z]!P4+:G@5[')]ON?D;_6O_"?4U7\N3_GF_\
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-45?M9]'8GV4>JN?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ (T# 2(  A$! Q$!_\0
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MI\?.8E*J3[ DG]:EHHH *\V^)_CO7_A_:VVH06VFWEG<S&$*ZNKH<$C)#8/
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0+L<@%E!S@^F>].HHH(/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex23-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& -P# 2(  A$! Q$!_\0
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MI47A_P"'L.G:O'KFM:M>:[K48*Q7-T<)"",'RXQPOZT =I7E@^*\A^(ATO\
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C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex23-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C > # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_+\1_P#/>P_[X:CR_$?_ #WL/^^&H#E\T:4]JLL$D:.T+. #)'PWYU)#"EO
MD*#Y$4*,^E9/E^(_^>]A_P!\-1Y?B/\ Y[V'_?#4!R^:-0VL9N&F.=[)Y9Y[
M4QK"%K#[$=WD[=O7G%9WE^(_^>]A_P!\-3DC\0>8N^>Q*9&["-G% <OF; &
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M2"LJ-Q@]CGN*LP6D<$T\JEB\S;F).>V ![5!9:;]C65&N99TD).V7! SU[4
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M$B!@PW8.>F[K0 R35(8[D0LDG50S[?E0GH"?6J<6M3221AK5D5C*2Q_A5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
